SUPPLEMENT

FY2023 — Results booklet

FY2023PDF · 50 pages2.4 MB
this is a link @ STUDIO5 to update please (please update to 30 June 2023)
for the year ended 30 June 2023
AUDITED RESULTS

-- 1 of 50 --

1
CONTENTS
DISCOVERY LIMITED
Registration number 1999/007789/06
A. Notes to the summarised financial statements
16 	A.1. Segment information
20 	A.2. Normalised profit from operations
21 	A.3. Earnings, headline earnings and normalised headline earnings
23 	A.4. Revenue from non-insurance activities
23 	A.5. Borrowings
25 	A.6. Restatement as a result of prior period error – reclassification of
unit-linked insurance contracts to unit-linked investment contracts
26 	A.7. Fair value hierarchy
28 	A.8. Cash generated by operations
B. Other significant items in these results
29 	B.1. Exchange rates to South African Rand used in the preparation of
these results
29 	B.2. Capital management, financial leverage ratio and covenants
31 	B.3 Impact of long-term interest rates in the SA and UK markets
32 	B.4. VitalityLife UK-impact of inflation rates
32 	B.5. VitalityCar
32 	B.6. VitalityInvest
33 	B.7. Consolidation of Discovery Unit Trusts
33 	B.8. Material transactions with related parties
33 	B.9. Major customers and other Discovery entities not part
of Discovery Group
34 	B.10. Changes in directorate
34 	B.11. Dividend declaration in respect of the year ended 30 June 2023
03 	Commentary
10 	Group statement of financial position
11 	Group income statement
12 	Group statement of other comprehensive income
13 	Group statement of cash flows
14 	Group statement of changes in equity
C. Accounting policies
35 	C.1. New accounting standards effective
35 	C.2 New accounting standards not yet effective
38 	C.3. Normalised headline earnings
39 	C.4. Basis of preparation
Embedded value statement
40 	Table 1: Group embedded value
41 	Table 2: Value of in-force covered business
42 	Table 3: Group embedded value earnings
42 	Table 4: Components of Group embedded value earnings
43 	Table 5: Experience variances
44 	Table 6: Methodology and assumption changes
45 	Table 7: Embedded value of new business
46 	Table 8: Embedded value economic assumptions
48 	Table 9: Embedded value sensitivity
48 	Table 10: Value of new business sensitivity
Annexure A
50 	New business annualised premium income
51 	Income from non-insurance business lines
52 	Administration

-- 2 of 50 --

2	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
2019
	2018
	2020
2021
2022
2023	
Normalised profit
	from operations	
(R million)
11 661
9 384
6 494
6 069
7 747
8 266
2019
	2018
	2020
2021
2022
2023	
Normalised headline earnings	
(R million)
7 678
5 816
3 406
3 747
5 035
5 401
2019
	2018
	2020
2021
2022
2023	
Embedded value	
(R million)
98 176
86 258
74 645
70 834
	71 217
65 624
2022
	2023
	2021
2020
2019
2018	
Core new business, excl
	products in run down
	of VitalityInvest and PAHI
	reinsurance (restated)	
(R million)
22 788
20 304
	19 668
18 769
17 943
16 137
2019
2018
2020
2021
2022
2023
Normalised headline earnings
(R million)
7 678
5 816
3 406
3 747
5 035
5 401
2022
2023
2021
2020
2019
2018
Core new business, excl
products in run down
of VitalityInvest and PAHI
reinsurance (restated)
(R million)
22 788
20 304
19 668
18 769
17 943
16 137
2019
2018
2020
2021
2022
2023
Normalised profit
from operations
(R million)
11 661
9 384
6 494
6 069
7 747
8 266
2019
2018
2020
2021
2022
2023
Embedded value
(R million)
98 176
86 258
74 645
70 834
71 217
65 624

-- 3 of 50 --

3
Commentary
GROUP OVERVIEW AND SALIENT GROUP RESULTS
The year under review was characterised by significant macroeconomic uncertainty, with several issues coalescing. The period saw
prolonged inflationary pressures, rising interest rates, a remarkably strong US dollar, increasing consumer pressure, and a cost-of-living
crisis in many regions. These pressures have constrained economic growth, following short-lived economic rebounds experienced by
many countries after the COVID-19 pandemic, with severe energy shortages in South Africa posing a further challenge.
Discovery Group delivered a robust performance for the 2023 financial year, with its three business
composites – South Africa (SA), United Kingdom (UK), and Vitality Global (VG) – all performing well. At a
Group level, normalised operating profit increased 24% to R11 661 million; headline earnings increased 5%
to R5 490 million; normalised headline earnings increased 32% to R7 678 million; and core new business
annualised premium income (API) increased 12% to R22 788 million.
Salient Group results
for the year ended 30 June 2023
Unit 	June 2023 	June 2022 	% Change
Group earnings
Normalised profit from operations 	R million 	11 661 	9 384 	24
Normalised headline earnings 	R million 	7 678 	5 816 	32
Headline earnings 	R million 	5 490 	5 204 	5
Basic earnings per share 	Cents 	785.4 	825.5 	(5)
Basic headline earnings per share 	Cents 	834.3 	792.4 	5
Basic normalised headline earnings per share 	Cents 	1 166.7 	885.5 	32
Group net asset value and embedded value
Net asset value 	R million 	63 974 	53 555 	19
Embedded value 	R million 	98 176 	86 258 	14
Annualised ROEV 	% 	13.2 	14.8
Basic embedded value per share 	R 	149.11 	131.29 	14
Financial leverage and capital management
Financial leverage ratio (FLR) 	% 	20.4 	23.8
Shareholder free cash increase 	R million 	397 	(1 225)
Business volume
Total income from non-insurance lines 	R million 	4 940 	3 439 	44
Core new business premium income 1 	R million 	22 788 	20 304 	12
Lives impacted 	Million 	40.5 	39.7 	2
1 Excluding products of VitalityInvest and Ping An Health Insurance (PAHI) reinsurance business in run down. The prior year has been restated accordingly
(refer Annexure A).
Delivering growth in quality
earnings and cashflow with a
robust balance sheet.
01
The Group’s focus in the period centred on the following, as explored in the sections that follow:
 
A clear growth strategy for each composite, evolving the
Vitality Shared-value model, and intensifying the focus on
key initiatives while closing those with marginal benefits.
02

-- 4 of 50 --

4	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Commentary continued
Delivering growth in quality earnings and cashflow with a robust balance sheet
The Group generated normalised operating profit growth of 24%. The businesses delivered strong premium and revenue growth, with core
new business API increasing 12% and positive customer retention and indexation, while total non-insurance income increased 44%.
Normalised operating profit growth was strong across each composite, as SA increased 22%, UK increased 21%, and VG increased 74%, with
the UK and VG benefitting from a weaker rand during the year. New business growth was strong in SA and the UK, with core new business
API increasing 11% and 26% respectively, while VG declined 1% as new business growth in Ping An Health Insurance (PAHI) was constrained
in a complex environment.
The headline earnings volatility caused by economic assumption changes is the rationale behind Discovery’s stated policy of normalising for the
impact of long-term interest rate movements in the presentation of normalised headline earnings. Although the interest rate changes impact
headline earnings, they have no impact on the operations of the Group, with little impact on the Group’s liquidity, cash flows, and solvency.
The sharp rise in both nominal and real interest rates across Discovery’s main insurance markets (SA and UK) negatively affected headline
earnings growth, and predominantly explains the difference between the 5% growth in headline earnings and the 32% growth in normalised
headline earnings. The impact of interest rates in the UK was more muted over the reporting year, as the hedging strategy proved effective,
with some gains resulting in increased discretionary margins. There was a more pronounced impact in SA, with the Discovery Life economic
assumptions adjustments amounting to R2 811 million, gross of tax.
The Group demonstrated continued financial resilience over the year as central liquidity remained strong, notwithstanding a R600 million
reduction in debt, and the financial leverage ratio (FLR) improved to 20%. Organic cash generation was robust during the year following growth
in quality earnings, a significant recovery in Discovery Life’s cash generation following elevated COVID-19-related claims in the prior period, and
the reduction in the cost of new initiatives. The robust balance sheet and cash positions support the recommencement of dividends.
The Group’s embedded value increased to R98 176 million, which represented a 13.2% return on embedded value (RoEV). The RoEV benefited
from R2.6 billion positive non-economic variances over the year, reflecting the positive dynamics of the Vitality Shared-value model. The weaker
rand exchange rate had a positive impact on the RoEV. This was offset by higher long-term interest rates in SA and the UK, which also decreased
new business margins.
A clear growth strategy per composite, evolving the Vitality Shared-value model, and
intensifying the focus on key initiatives while closing those with marginal benefits
High levels of engagement in the Vitality Shared-value model, together with the efficacy of the model, underpinned the strong growth in
profit and cash generation, retention of customers, and robust levels of new business. This demonstrates the model’s resilience in a
challenging and volatile macroeconomic environment. The Group is now focused on evolving the model into an integrated value chain with
bespoke modules to drive growth and market leadership across each of the composites.
Spend on new initiatives reduced significantly from 18%* of normalised operating profit in the prior year to 10.6% in the current year for
continuing operations, excluding the impairment and closure costs of certain UK initiatives. The reduction in spend has tracked that of
Discovery Bank, the Group’s most significant initiative, as spend remained well within plan despite accelerated client acquisition.
The following table provides a summary of the earnings and new business performance by composite:
Normalised
profit from
operations
(Current year,
in ZAR million)
% change
(Current
year vs
prior year)
Core new
business API
(Current
year, in
ZAR million)
% change
(Current
year vs
prior year)
Discovery Health 	3 854 	7 	8 678 	19
Discovery Life 	4 807 	19 	2 838 	12
Discovery Invest 	1 560 	30 	3 050 	4
Discovery Insure – Personal1 	62 	(138) 	1 249 	0
Discovery Bank 	(767) 	(23)
Other SA initiatives 	(312) 	28 	631 	(25)
Central costs 	(124) 	n/a
SA Composite2 	9 096 	22 	16 818 	11
VitalityHealth 	1 283 	(3) 	2 064 	19
VitalityLife 	1 039 	55 	1 721 	37
Closure costs of VitalityInvest and Vitality Car 	(455) 	(1) 	3 	3
Other UK initiatives and head office costs 	(79) 	32
UK Composite 	1 788 	21 	3 785 	26
Vitality Network 	411 	26
VHI – Ping An Health Insurance (PAHI) 	596 	76 	2 185 	(1)3
VHI – Other 	(195) 	1
Other VG 	(35) 	46
Vitality Global 	777 	74 	2 185 	(1)3
Normalised profit from operations 2 	11 661 	24
Normalised headline earnings 	7 678 	32
Core new business API2,3 	22 788 	12
* As a percentage of normalised profit from operations before new initiatives.
1 Includes Discovery Insure’s share of equity accounted losses of its associates of R19 million (prior loss: R13 million).
2 Includes for SA Vitality: normalised profit from operations of R16 million (prior: R9 million); core new business API of R372 million (prior: R256 million).
3 Core new business API excludes products of VitalityInvest and PAHI reinsurance business in run down (refer Annexure A).

-- 5 of 50 --

5
BUSINESS-SPECIFIC PERFORMANCE
South Africa, including new initiatives
The SA composite’s normalised operating profit increased by 22% to R9 096 million and new business by 11% to R16 818 million. Discovery
Health showed strong growth across all metrics with prior investment in technology driving efficiencies and continued innovation. Discovery
Life had a resilient performance with positive variances, with Group Life returning to profit. Discovery Invest generated significant growth in
profit, given higher investment markets and other in-period gains. Discovery Insure delivered on its profit turnaround, following actions
taken in previous periods. Discovery Bank continued with excellent progress across all metrics, as acquisition of quality clients accelerated
over the year. Further investment in product innovation and digital capabilities continues to evolve the Bank into a composite-maker in the
Discovery retail ecosystem. Investment into other initiatives increased for the year, as Discovery Business Insurance and Umbrella Funds
improved slightly, while Vitality Health International (Africa) expanded from a low prior base.
Unit 	June 2023 	June 2022 	% Change
Net non-interest revenue (NIR) 	R million 	943.1 	632.9 	49
Net interest income (NII) 	R million 	573.7 	317.6 	81
Normalised loss from operations 	R million 	767.3 	990.3 	23
Retail deposits 	R billion 	14.3 	10.6 	36
Advances 	R billion 	5.2 	4.3 	22
Credit loss ratio (CLR) 	% 	3.04 	2.18 	39
Number of accounts 	Number 	1 625 912 	1 023 790 	59
Number of clients 	Number 	702 131 	470 220 	49
Discovery Bank’s (DB) operating loss was 23% better than the prior year and the operating loss before new business acquisition costs
was 39% better than the prior year, as growth continued to exceed expectations. DB has accelerated client acquisition and improved
credit penetration through a quality-focused credit strategy. DB delivered on the medium-term target of averaging 1,000 new clients a
day for January to June 2023, which was 50% higher than the equivalent prior year period, with quality remaining excellent. Total clients
exceeded 700,000 by the end of June 2023, with significant progress towards the target of one million clients by 2026.
Advances have grown steadily given increased credit application volumes (+56% compared to prior year) and increased card usage. DB’s
share of new credit issued was 15.7% (by value) of credit card facilities in the second quarter of 2023, up from 10.9% the prior year. The
quality-focused credit strategy was evidenced by the credit loss ratio remaining within the long-term targets, despite the challenging
macroeconomic environment. Continuous operational enhancements have been implemented with a focus on improving collections,
as macroeconomic challenges are expected to continue.
Non-interest revenue grew strongly with increasing interchange and fee income per client, higher upgrades than the prior year, and
increased transactions, debit orders and salary deposits. Clients’ utilisation of DB’s transaction capabilities grew, with total payments
increasing 56%, by value, and total spend increasing by 48%.
Discovery Bank
Unit 	June 2023 	June 2022 	% Change
Normalised operating profit 	R million 	3 854 	3 600 	7
New business API 	R million 	8 678 	7 292 	19
Revenue 	R million 	10 211 	9 340 	9
Non-scheme as revenue % of total revenue 	% 	14.7 	14.0
Lives under administration 	Number 	3 827 895 	3 772 435 	1
Discovery Health (DH) experienced robust operating profit growth, despite elevated costs during the first half of the reporting year for
technology and infrastructure spend. The investment in technology continues to drive efficiencies through increased digital engagement,
further differentiating and widening the efficiency of DH’s services.
DH continued to deliver on top-line growth metrics with solid new business API and revenue growth despite a challenging market
environment. Non-medical scheme products – Flexicare, Gap Cover and Healthy Company – performed well and total non-scheme
revenue now represents almost 15% of total DH revenue.
In addition to the open medical scheme, Discovery Health Medical Scheme (DHMS), DH also administers 17 closed medical schemes
that performed well during the year. DH has successfully secured the administration of the Sasolmed Medical Scheme, commencing
1 January 2024. DHMS’s market share has continued to grow, achieving 57.8%, and it remains in a strong financial position with solvency
of 35.1% at December 2022, well over the 25% regulatory requirement.
Discovery Health
June 2023
June 2023

-- 6 of 50 --

6	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Commentary continued
Unit 	June 2023 	June 2022 	% Change
Normalised operating profit 	R million 	4 807 	4 028 	19
New business API 	R million 	2 838 	2 543 	12
Premium income 	R million 	16 620 	15 041 	10
Solvency ratio (including Invest) 	% 	188 	173
RoEV (including Invest) 	R million 	8 	10
VNB margin 	% 	2.5 	5.3
Discovery Life’s (DL) normalised operating profit increased 19%, driven by a resilient operational performance in Individual Life, and
Group Life returning to profit following the severe impact of COVID-19 in the prior year. Claims experience was in line with expectations
for the year, moderating in the second half from the slightly elevated morbidity claims in the first half of the reporting year. Customer
retention was solid, despite increasing consumer pressure: lapse experience was impressive, although policy alterations worsened as
clients adjusted to the environment.
New business API increased by 12%, aided by solid automatic contribution increases, leading to DL’s market share gain from 28.4% for
Q2 2022 to 30.2% for Q2 2023. Embedded value growth was impacted by material movements in the shape and level of yield curves
combined with a short-term strengthening of lapse assumptions in anticipation of the continued macroeconomic challenges. The value
of new business (VNB) was impacted similarly, with higher unit costs, following a slight decline in new business production, being a
further contributor to the reduction in margin.
Financial resilience was reaffirmed as the solvency cover ratio improved and there was a strong recovery in cashflow to R2 126 million,
from a negative R245 million cashflow in the prior year, given elevated COVID-19-related claims. The liquidity coverage was significantly
above 100%.
Discovery Life
Unit 	June 2023 	June 2022 	% Change
Assets under administration 	R billion 	140.3 	121.7 	15
Assets under management 	R billion 	95 	81 	17
% linked assets in Discovery funds 	% 	80 	80 	0
Net client cash flows 	R billion 	5.9 	5.8 	2
New business API 	R million 	3 050 	2 920 	4
Fee income 	R million 	3 099 	2 834 	9
Normalised operating profit from operations 	R million 	1 560 	1 204 	30
Discovery Invest’s normalised operating profit increased 30%, following improved growth in underlying assets and additional gains over
the year. Assets under management ended the year 17% higher, with average monthly assets 9% higher than the prior year, lifting asset-
based revenues. The result further benefited from in-period gains through the implementation of an optimised asset-liability matching
strategy on the guaranteed return plan and life annuity portfolios, supported by higher yields. The release of a previously raised tax
reserve, relating to the 1 July 2022 implementation of a tax amendment, boosted operating profit, countered by a corresponding increase
in tax payable. New business and net flows were impacted by lower net flows into discretionary savings products across the industry,
however, increased demand for guaranteed products, as well as improved sales of compulsory savings products, partially offset this trend.
Discovery Invest
Unit 	June 2023 	June 2022 	% Change
Personal lines 	R million 	81 	(149) 	(154)
Equity accounted losses 	R million 	(19) 	(13) 	46
Normalised operating profit/(loss) 	R million 	62 	(162) 	(138)
Operating margin personal lines 	% 	1.53 	(3.13)
New business API personal lines 	R million 	1 249 	1 246 	0.3
Gross written premiums 	R million 	5 259 	4 762 	10.4
Discovery Insure (DI) personal lines continued to deliver on its margin recovery plan, with further improvement in the second half of
the reporting period. Increased power surge claims driven by loadshedding and increased severity of vehicle theft made for a
challenging environment. These have been mitigated by selective repricing initiated in January 2022, claims cost reduction initiatives,
and various risk mitigations applied over the past year. Further, operational changes to reduce the cost of power surge claims and
vehicle theft risk have been implemented. New business was largely unchanged as DI remains focused on growth of quality new
business. Enhancements to the Vitality Drive programme have further emphasised the focus on driving behaviour, and appropriate
risk-based pricing initiatives have ensured that top-line written premium growth remained strong.
Discovery Insure

-- 7 of 50 --

7
UNITED KINGDOM, INCLUDING NEW INITIATIVES
The UK composite‘s normalised operating profit increased by 14% to £83.4 million (up 21% to R1 788 million). Earned premiums increased
by 11% year-on-year to £989.2 million (up 17% to R21 199 million), and total lives insured increased by 11% to 1.72 million. Core new
business API was strong, increasing by 19% to £177 million (26% to R3 785 million), excluding VitalityInvest (VI), following the prior decision
to close the business.
The UK composite has continued its focus on actions that position it for strong sustainable growth, without recourse to funding from the
Group. The decision to close VI, and more recently the decision to terminate Vitality Car (VC), will allow the composite to focus its attention
on continuing to drive success in the core health and life insurance market. VitalityHealth has seen significant success from its evolution into
a comprehensive, digital-first health insurer as it builds healthcare capabilities in an environment of continued healthcare demand and strain
in the UK. VitalityLife is now largely self-funding and the agreed deferral of the part VII agreement with Prudential in May 2022, provides
greater financial flexibility at a significantly reduced cost from May 2023. This positive outlook and significantly improved financial position
culminated in the UK composite recently receiving an independent credit rating of ‘A’ from Fitch.
VitalityLife’s profit was boosted by positive operating variances, benefiting from significantly higher premium inflation indexation.
VitalityHealth’s profits declined slightly off a strong prior result, given elevated new business strain from strong sales and the industry-wide
return of private medical insurance (PMI) claims post the COVID-19 pandemic. Other UK costs were elevated by the tail-end of closure costs
relating to VI and a £8.8 million (R189 million) impairment of VC’s intangible assets following a decision to terminate the business, given the
challenging market environment. VI’s closure will be completed in this calendar year, with the regulatory approval now in place.
Unit 	June 2023 	June 2022 	% Change
Normalised operating profit 	GBP million 	59.9 	65.6 	(9)
R million 	1 283 	1 328 	(3)
Earned premiums1 	GBP million 	623.6 	560.2 	11
R million 	13 364 	11 345 	18
New business API 	GBP million 	96.3 	85.8 	12
R million 	2 064 	1 738 	19
Lives covered 	Number 	959 075 	845 224 	13
1. Excluding the UPR adjustment.
VitalityHealth’s (VH) normalised operating profit declined slightly off a strong prior year result as strong new business resulted in
elevated new business strain and PMI claims returned to pre-COVID-19 levels with higher inflation. Higher PMI claims were partly offset
by the release of the remaining £15.2 million (R326 million) unearned premium reserve (UPR) overlay. This was set up in the prior year
to cover the expected additional claims in the current year. There has also been increased investment into business and service
capabilities to further capitalise on the opportunity created by continued healthcare demand and strain in the UK.
Claims authorisations increased 27% in the second half of the reporting year as compared with the equivalent prior year. The impact of
higher claims authorisations has been balanced by a lower cost per claim, through a combination of lower severity from new conditions
and continued effective risk management and servicing. Lives covered increased 13% and earned premiums grew by 11% reflecting the
strong new business and excellent retention. Cash generation was robust, with the back book generating £99.4 million (R2 130 million) in
cash. After new business acquisition costs and investment initiatives, the book generated a £5.6 million (R120 million) cash surplus.
The rapid rise in industry claims follows an extended period of reduced healthcare utilisation, caused by the COVID-19 pandemic.
Through this period, VitalityHealth applied its modelling capabilities to ensure it had provided appropriately for the expected catch-up
in claims. This was enabled through setting up UPR overlays in the 2021 and 2022 reporting years, as well as by accelerating the
repayment of reinsurance arrangements by £40 million (R823 million) in the 2021 reporting year. As explained in prior reporting, the
benefit of the accelerated repayment was evenly spread in both the 2022 and 2023 reporting years and will not recur in the 2024 period.
Vitality Health
Unit 	June 2023 	June 2022 	% Change
Normalised operating profit 	GBP million 	48.5 	33.1 	47%
R million 	1 039 	671 	55%
Earned premium 	GBP million 	365.6 	333.3 	10%
R million 	7 835 	6 750 	16%
New business API 	GBP million 	80.3 	62.0 	30%
R million 	1 721 	1 256 	37%
Lives covered 	Number 	764 699 	702 879 	9%
VNB margin 	% 	(1%) 	1.4% 	n/a
VitalityLife’s (VL) normalised operating profit grew by 47%, in GBP. The result was particularly strong given positive operating experience
variances over the year, most notably the exceptional benefit of improved premium indexation in the higher inflationary environment.
The result had an overall £18.3 million (R392 million) net favourable benefit for the year. This benefit is a combination of a multi-year
focus on continuous improvement of the quality of the portfolio, including an increase in the proportion of index-linked policies, as well
as implementation of persistency initiatives. New business API increased by 30%, strongly supported by the new pricing engine, the
launch of simplified product enhancements, incorporating deeper shared value and the high take up of indexation increases. At the
same time, higher long-term interest rates negatively impacted VNB margins. Earned premiums and insured lives increased 10% and
9%, respectively, highlighting the strong sales and solid retention performance, despite the higher inflationary environment.
Vitality Life

-- 8 of 50 --

8	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Commentary continued
VITALITY GLOBAL, INCLUDING NEW INITIATIVES
Vitality Global (VG) includes Vitality Network (VN), as well as Ping An Health Insurance (PAHI) within Vitality Health International (VHI).
VG increased operating profits by 49% to US$44 million (74% to R777 million).
Unit 	June 2023 	June 2022 	% Change
Revenue 	US$ million 	69.5 	67.7 	3
R million 	1 236 	1 031 	20
Normalised operating profit 	US$ million 	23.1 	21.4 	8
R million 	411 	325 	26
Integrated API by insurance partners 	US$ million 	1 414 	1 424 	(1)
R million 	25 155 	21 673 	16
Number of lives 	Million 	3.7 	3 	23
VN grew normalised operating profits 8% to US$23 million. Revenues were curtailed by slow post-pandemic recoveries in Asia Pacific
markets and significant US dollar strength against most global currencies over the reporting year, in particular relative to the Yen.
Increased insurance partner membership was supported by growth in existing markets and new market launches, as new growth
opportunities emerged over the year with the launch of TATA AIA Vitality in India, a more comprehensive roll-out of Vitality in Manulife
Canada, and the expansion of the partnership in Latin America with Prudential. The business continues to drive product innovation and
delivery through Vitality1, enhancing the platform’s performance and driving operating efficiencies.
Vitality Network continues to positively impact its partner businesses through the Vitality Shared-value model, growing policy sales,
reducing lapse rates and making people healthier. At the highest level, the model has been shown to create a profit margin up to three
times that of traditional insurance models, while decreasing the cost of insurance for clients. Among partners, longitudinal analyses
have shown mortality improvements above expectations of over 40% for most engaged Vitality members. The success of the model is
driving deeper growth within existing markets and continued opportunity for expansion.
Vitality Network
Unit 	June 2023 	June 2022 	% Change
PAHI (25%) 	R million 	596 	338 	76
Other VHI 	R million 	(195) 	(193) 	1
Normalised operating profit-total 	R million 	401 	145 	177
PAHI
New business PAHI own licence 	R million 	2 185 	2 214 	(1)
New business PAHI reinsurance 	R million 	184 	669 	(72)
New business PAHI total (25%) 	R million 	2 369 	2 883 	(18)
Written premium-own licence 	R million 	36 533 	29 944 	22
Written premium reinsurance 	R million 	13 558 	15 251 	(11)
Total written premium (100%) 	R million 	50 091 	45 196 	11
PAHI profit before income and gains (100%) 	R million 	2 114 	1 853 	14
PAHI pre-tax profit (100%) 	R million 	3 398 	2 453 	39
VHI’s profit increased by 177% as the Group’s share of PAHI’s after-tax operating profit, less Discovery’s costs to support the business,
increased 76%. PAHI performed well in a complex operating environment in China, with a solid operational performance and
significantly improved investment returns, and maintained its robust balance sheet, with a comprehensive solvency ratio of 267%. The
business continues to invest into globalising its unique healthcare capabilities, with additional investment this year into the US to
upgrade product capabilities and to expand sales and marketing capacity, with some positive early traction already achieved.
New business on the PAHI insurance licence declined 1% (declined 9% in RMB), constrained by widespread lockdowns in the first half
of 2023 reporting year, a complex economic backdrop, the impact of the first major COVID-19 wave, and challenges experienced by
several channels. Written premium on the PAHI insurance licence increased 22% (13% in RMB), whereas total written premiums
increased 11% (2% in RMB), given the gradual run-down of Ping An Life’s business reinsured by PAHI, which was anticipated. As of June 2023,
PAHI insurance licence premiums grew faster than the relatively flat market, by 10 percentage points, supported by continued
retention initiatives.
Amplify Health continued to invest in technology and analytics to build its integrated health solutions for the pan-Asian market. It
acquired AiDA Technologies, a leading provider of artificial intelligence solutions to companies across Asia Pacific, to accelerate the
deployment of the Fraud Waste and Abuse solution and develop new products such as Smart Claims+. Amplify Health made its first
solution sale to AIA Malaysia, aimed at automating claims processing and detecting fraud and waste in health insurance claims. Strong
income generated from the accounting treatment of the Amplify Health transaction exceeded Amplify Health’s equity-accounted losses
for the year, resulting in a profit for the Group overall.
Vitality Health International

-- 9 of 50 --

9
TRANSITION TO IFRS 17 – WITH OVERALL VALUE LARGELY UNCHANGED, EFFECTIVELY
REALLOCATED FROM EQUITY TO MARGIN AS A STORE OF VALUE FOR FUTURE PROFITS
Discovery Group is adopting the IFRS 17 accounting standard for Insurance Contracts, which will replace the previous standard, IFRS 4
Insurance Contracts. The new standard will be adopted for Discovery Group’s 2024 financial year, and as a result, earnings will be reported
under this standard for the first time at its interim reporting for the 2024 financial year. At its interim reporting for the 2023 financial year,
the Group highlighted the expected increase in reserves under IFRS 17 because of an increase in the IFRS 17 margins compared with the
IFRS 4 margins, leading to a reduced equity position on transition.
While the new standard affects the timing of profit recognition, applied retrospectively, it does not result in any direct change to cashflow,
nor the underlying risk and reward of contracts. There is no material impact on embedded value, regulatory or economic solvency, the
capital position or capital management; and the ability to pay a dividend is unaffected. The change in standard will impact the disclosures
pertaining to insurance contracts in the financial statements.
The major impact of the change from IFRS 4 to IFRS 17 arises from the long-term life insurance businesses. Discovery’s life businesses, both
Discovery Life and particularly VitalityLife in the UK, are relatively young, high-growth, long-term, largely individual protection businesses
with high upfront acquisition costs. For Discovery, the most significant impact resulting from the transition is that IFRS 17 is both narrower
and more specific in the definition of which expenses can be directly attributed as part of the measurement of the insurance contract. The
impact of the change in definition of directly attributable expenses results in the earlier recognition of expenses, resulting in higher profit
recognised under IFRS 4 than under IFRS 17 in earlier years, and lower in later years.
IFRS 17 also has a more granular grouping of contracts into cohorts, as opposed to a broader portfolio under IFRS 4, where margins on
profitable business would be used to offset the valuation losses of onerous business. Under IFRS 17, losses from onerous contracts are
immediately expensed in profit and loss. This further reduces equity on transition, leaving the higher unencumbered margin on profitable
business to emerge in the future.
On transition from IFRS 4 to IFRS 17, the overall value is largely unchanged, such that the reduction in shareholder equity has a resulting
increase in the contractual service margin (CSM), which should be seen as a store of value to be released as future profit. As at 1 July 2022, being
the first balance sheet to be restated once the standard is fully adopted, shareholder equity is expected to decrease by between R12 billion and
R13 billion (net of tax) on transition and the CSM concomitantly to increase by between R14.5 billion and R15.5 billion (gross of tax).
Considering the above for Discovery, at the point when IFRS 17 profits equal IFRS 4 profits, the differential in both the margin and equity impact
under IFRS 17 versus IFRS 4 is theoretically at its highest. Notably, beyond this “cross-over” point, IFRS 17 earnings will be at a level higher than
they would have been under IFRS 4 and would be expected to continue to be higher going forward, because of the higher CSM being released
over time. Discovery Life, the larger life business, is expected to reach the cross-over point in the short term and in the interim, its IFRS 17 profits
are not expected to differ significantly from its IFRS 4 normalised operating profit. In the case of VitalityLife, which is still relatively young and
growing rapidly, the impact on earnings is expected to be more pronounced and it will take longer to reach its cross-over point. Given this
dynamic, while Discovery Group’s cross-over will lag that of Discovery Life, its earnings as a whole, under IFRS 17, are not expected to be
significantly different to the IFRS 4 normalised operating profit in the interim, as the other businesses are largely unaffected. This broad
expectation is subject to any potential volatility that may arise, particularly in respect of VitalityLife given its relative immaturity.
IFRS 17 is also expected to reduce economic volatility, through the election to treat insurance finance income and expense through the
statement of other comprehensive income (OCI), most notably the impact of changes in interest rates on the valuation of insurance
contracts. The strengthened IFRS 17 margins result in a higher release of profits over time and in less volatility due to its ability to absorb
negative basis variances of non-economic events, while the election of OCI results in less volatility because of its ability to manage variances
in financial risks. This is largely in line with Discovery’s current presentation of normalised operating profit.
PROSPECTS AND DIVIDEND
Discovery’s growth strategy is based on the efficacy, repeatability and scalability of its Vitality Shared-value model. Since this model is
inherently a new business model, growth is pursued through organic growth and global partnerships. The performance during the period
has enhanced the Group’s confidence in this strategy and the Group is now focused on evolving the model to a platform with an integrated
value chain to drive strong future growth.
The strong balance sheet and liquidity position at both the Group level and at the regulated entity levels, in addition to the cash generative
capacity of the Group, support the recommencement of ordinary dividends, declared at 110 cents per share, in respect of the second half-
year’s earnings. In future, the Group anticipates annual ordinary dividends to be covered approximately 5 times by normalised headline
earnings. Interim ordinary dividends are expected to be paid in the range of 30% to 40% of the expected total annual ordinary dividend, in
line with market practice, with the remainder of the dividend to be paid as a final dividend.
NOTES TO ANALYSTS
Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company’s external auditors.
Discovery has published supplemental unaudited information on the website. For this and other results information, visit
https://www.discovery.co.za/corporate/investor-relations and go to Financial and annual reports.
On behalf of the Board
ME Tucker 	A Gore
Chairperson 	Group Chief Executive
Sandton
20 September 2023

-- 10 of 50 --

10	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Group statement of financial position
at 30 June 2023
R million 	Notes
Group
2023
Restated 1
Group
2022
Restated1
Group
1 July 2021
Assets
Goodwill 	5 406 	4 912 	4 879
Intangible assets 	6 982 	6 539 	6 371
Property and equipment 	3 910 	3 811 	4 188
Assets arising from insurance contracts 	63 865 	56 645 	50 483
Deferred tax asset 	4 404 	4 455 	3 948
Deferred acquisition costs 	799 	640 	585
Assets arising from contracts with customers 	2 201 	1 692 	1 375
Investment in equity-accounted investees 	7 024 	6 008 	3 459
Financial assets
– Loans and advances to customers at amortised cost 	4 702 	3 944 	3 361
– Investments at amortised cost 	9 910 	7 161 	5 604
– Investments at fair value through profit or loss 	A.7. 	155 426 	141 494 	130 937
– Derivative financial instruments at fair value through profit or loss 	119 	276 	249
Insurance receivables, contract receivables and other receivables 	16 059 	13 113 	10 533
Non-current assets held for sale 	– 	171 	–
Current tax asset 	41 	220 	391
Reinsurance contracts 	709 	511 	445
Cash and cash equivalents 	20 370 	19 775 	20 013
TOTAL ASSETS 	301 927 	271 367 	246 821
Equity
Capital and reserves
Ordinary share capital and share premium 	10 351 	10 178 	10 151
Perpetual preference share capital 	779 	779 	779
Other reserves 	8 622 	3 621 	1 935
Retained earnings 	44 218 	38 972 	33 550
Equity attributable to equity holders of the Company 	63 970 	53 550 	46 415
Non-controlling interest 	4 	5 	4
TOTAL EQUITY 	63 974 	53 555 	46 419
Liabilities
Liabilities arising from insurance contracts 	114 807 	108 067 	100 041
Liabilities arising from reinsurance contracts 	14 669 	13 192 	12 525
Deferred tax liability 	9 559 	9 335 	8 814
Contract liabilities to customers 	656 	944 	776
Financial liabilities
– Borrowings at amortised cost 	A.5. 	20 586 	20 584 	19 493
– Other payables 	14 780 	15 123 	14 904
– Deposits from customers 	14 333 	10 881 	8 985
– Investment contracts at fair value through profit or loss 	48 044 	38 637 	33 354
– Derivative financial instruments at fair value through profit or loss 	20 	202 	826
Employee benefits 	334 	320 	315
Current tax liability 	165 	527 	369
TOTAL LIABILITIES 	237 953 	217 812 	200 402
TOTAL EQUITY AND LIABILITIES 	301 927 	271 367 	246 821
1 The comparative information has been restated. Refer to note A.6. for detail.
The order in which individual line items are presented in the Statement of financial position has been amended to better reflect their respective liquidity, as far
as possible, from least liquid to the most liquid items. No values were reclassified or restated between line items.

-- 11 of 50 --

11
Group income statement
for the year ended 30 June 2023
R million 	Notes
Group
2023
Restated1
Group
2022
Insurance premium revenue 	59 671 	58 312
Reinsurance premiums 	(10 136) 	(8 262)
Net insurance premiums 	49 535 	50 050
Fee income from administration business 	14 757 	12 752
Vitality income 	3 891 	3 495
Net banking fee and commission 	965 	645
Banking fee and commission income 	1 292 	853
Banking fee and commission expense 	(327) 	(208)
Net banking interest and similar income 	574 	318
Bank interest and similar income using the effective interest rate 	1 318 	811
Bank interest and similar expense using the effective interest rate 	(744) 	(493)
Investment income using the effective interest rate method 	772 	296
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	14 373 	(1 825)
Other income 	1 544 	1 341
Net income 	86 411 	67 072
Net claims and policyholders’ benefits 	(40 135) 	(30 715)
Claims and policyholders’ benefits 	(46 746) 	(38 022)
Insurance claims recovered from reinsurers 	6 611 	7 218
Recapture of reinsurance 	– 	89
Acquisition costs 	(6 213) 	(4 758)
Marketing and administration expenses 	(28 905) 	(25 209)
Amortisation of intangibles from business combinations 	(56) 	(59)
Expected credit losses 	(139) 	(67)
Recovery of expenses from reinsurers 	3 593 	2 859
Net transfer to/from assets and liabilities under insurance contracts 	(322) 	(1 297)
– Change in assets arising from insurance contracts 	5 860 	5 786
– Change in assets arising from reinsurance contracts 	135 	63
– Change in liabilities arising from insurance contracts 	(3 992) 	(6 738)
– Change in liabilities arising from reinsurance contracts 	(328) 	(577)
– Economic assumptions adjustments net of discretionary margins 	(1 997) 	169
Fair value adjustment to liabilities under investment contracts 	(5 572) 	32
Profit from operations 	8 662 	7 858
Finance costs 	(1 941) 	(1 658)
Foreign exchange gains 	150 	155
Impairment of goodwill 	(9) 	–
(Losses)/gains on dilution and/or disposal of equity-accounted investments 	(5) 	33
Reversal of impairment of equity-accounted investments 	– 	134
Share of net profits from equity-accounted investments 	515 	422
Profit before tax 	7 372 	6 944
Income tax expense 	(2 052) 	(1 465)
Profit for the year 	5 320 	5 479
Profit attributable to:
– Ordinary shareholders 	5 258 	5 422
– Preference shareholders 	69 	56
– Non-controlling interest 	(7) 	1
5 320 	5 479
Earnings per share for profit attributable to ordinary shareholders of the
Company during the year (cents):
– Basic 	A.3. 	785.4 	825.5
– Diluted 	A.3. 	781.5 	817.8
1 The comparative information has been restated. Refer to note A.6. for detail.

-- 12 of 50 --

12	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Group statement of other comprehensive income
for the year ended 30 June 2023
R million
Group
2023
Group
2022
Profit for the year 	5 320 	5 479
Items that are or may be subsequently reclassified to profit or loss:
Currency translation differences 	4 107 	467
– Unrealised gains 	4 222 	467
– Tax on unrealised gains 	(115) 	–
Cash flow hedges 	76 	309
– Unrealised gains 	76 	322
– Tax on unrealised gains 	– 	(2)
– Gains recycled to profit or loss 	(1) 	(10)
– Tax on recycled gains 	1 	(1)
Share of other comprehensive income from equity-accounted investments 	419 	601
– Change in fair value of debt instruments at fair value through other comprehensive income 	(23) 	17
– Currency translation differences 	442 	584
Items that may not be reclassified to profit or loss:
Share of other comprehensive income from equity-accounted investments 	7 	–
– Change in fair value of equity instruments at fair value through other comprehensive income 	7 	–
Other comprehensive income for the year, net of tax 	4 609 	1 377
Total comprehensive income for the year 	9 929 	6 856
Attributable to:
– Ordinary shareholders 	9 867 	6 799
– Preference shareholders 	69 	56
– Non-controlling interest 	(7) 	1
Total comprehensive income for the year 	9 929 	6 856

-- 13 of 50 --

13
Group statement of cash flows
for the year ended 30 June 2023
R million 	Notes
Group
2023
Group
20221
Cash flow from operating activities 	2 549 	3 597
Cash generated by operations 	A.8. 	8 308 	20 943
Purchase of investments held to back policyholder liabilities 	(62 773) 	(56 588)
Proceeds from disposal of investments held to back policyholder liabilities 	55 908 	38 411
Cash generated from operating activities 	1 443 	2 766
Dividends received 	728 	600
Interest received 	3 718 	2 824
Interest paid 	(1 501) 	(1 412)
Taxation paid 	(1 839) 	(1 181)
Cash flow from investing activities 	(2 236) 	(4 704)
Purchase of financial assets 	(30 966) 	(32 878)
Proceeds from disposal of financial assets 	30 932 	31 482
Purchase of property and equipment 	(551) 	(275)
Proceeds from disposal of property and equipment 	2 	25
Purchase of software and other intangible assets 	(1 760) 	(1 567)
Proceeds from disposal of software and other intangible assets 	– 	2
Acquisition of subsidiary 	(3) 	–
Additional investment in equity-accounted investments 	(182) 	(1 593)
Proceeds from sale of non-current asset held for sale 	184 	–
Dividends from equity-accounted investments 	108 	100
Cash flow from financing activities 	(1 234) 	518
Dividends paid to preference shareholders 	(69) 	(56)
Proceeds from borrowings 	7 442 	3 261
Repayment of borrowings 	(8 607) 	(2 687)
Net decrease in cash and cash equivalents 	(921) 	(589)
Cash and cash equivalents at beginning of the year 	19 619 	20 013
Exchange gains on cash and cash equivalents 	1 639 	195
Cash and cash equivalents including bank overdraft at end of the year 	20 337 	19 619
Reconciliation to Statement of financial position
Cash and cash equivalents 	20 370 	19 775
Bank overdraft included in borrowings at amortised cost 	(33) 	(156)
Cash and cash equivalents including bank overdraft at end of the year 	20 337 	19 619
1 The presentation of the Statement of cash flows has been aligned to the Annual financial statements. The previous year has been aligned accordingly
for comparability.

-- 14 of 50 --

14	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023	 	15
Group statement of changes in equity
for the year ended 30 June 2023
Attributable to equity holders of the Company 	Attributable to equity holders of the Company
R million
Share capital
and
share
premium
Preference
share
capital
Share-based
payment
reserve
Investment
reserve 1
Translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-
controlling
interest
Total
Equity
Group 2023
At beginning of the year 	10 178 	779 	798 	35 	2 823 	(35) 	38 972 	53 550 	5 	53 555
Total comprehensive income for the year 	– 	69 	– 	(16) 	4 549 	76 	5 258 	9 936 	(7) 	9 929
Profit for the year 	– 	69 	– 	– 	– 	– 	5 258 	5 327 	(7) 	5 320
Other comprehensive income 	– 	– 	– 	(16) 	4 549 	76 	– 	4 609 	– 	4 609
Transactions with owners 	173 	(69) 	392 	– 	– 	– 	(12) 	484 	6 	490
Share issue 	514 	– 	– 	– 	– 	– 	– 	514 	– 	514
Increase in treasury shares 	(514) 	– 	– 	– 	– 	– 	– 	(514) 	– 	(514)
Delivery of treasury shares 	173 	– 	(161) 	– 	– 	– 	(12) 	– 	– 	–
Acquisition of subsidiaries with non-controlling interest 	– 	– 	– 	– 	– 	– 	– 	– 	6 	6
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	553 	– 	– 	– 	– 	553 	– 	553
Dividends paid to preference shareholders 	– 	(69) 	– 	– 	– 	– 	– 	(69) 	– 	(69)
At end of the year 	10 351 	779 	1 190 	19 	7 372 	41 	44 218 	63 970 	4 	63 974
Group 2022
At beginning of the year 	10 151 	779 	489 	18 	1 772 	(344) 	33 550 	46 415 	4 	46 419
Total comprehensive income for the year 	– 	56 	– 	17 	1 051 	309 	5 422 	6 855 	1 	6 856
Profit for the year 	– 	56 	– 	– 	– 	– 	5 422 	5 478 	1 	5 479
Other comprehensive income 	– 	– 	– 	17 	1 051 	309 	– 	1 377 	– 	1 377
Transactions with owners 	27 	(56) 	309 	– 	– 	– 	– 	280 	– 	280
Share issue 	443 	– 	– 	– 	– 	– 	– 	443 	– 	443
Increase in treasury shares 	(443) 	– 	– 	– 	– 	– 	– 	(443) 	– 	(443)
Delivery of treasury shares 	27 	– 	(17) 	– 	– 	– 	– 	10 	– 	10
Employee share option schemes:
– Value of employee services 	– 	– 	326 	– 	– 	– 	– 	326 	– 	326
Dividends paid to preference shareholders 	– 	(56) 	– 	– 	– 	– 	– 	(56) 	– 	(56)
At end of the year 	10 178 	779 	798 	35 	2 823 	(35) 	38 972 	53 550 	5 	53 555
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments
measured at FVOCI, in terms of IFRS 9 Financial Instruments.

-- 15 of 50 --

16	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023	 	17
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS
A.1. 	Segment information
R million
SA
Health
SA
Life
SA
Invest
SA
Insure2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments 3
IFRS
total
Group 2023
Income statement
Insurance premium revenue 	245 	16 620 	15 104 	5 177 	– 	– 	13 670 	7 835 	1 808 	60 459 	(788) 	59 671
Reinsurance premiums 	(1) 	(3 852) 	– 	(414) 	– 	– 	(2 149) 	(4 277) 	(231) 	(10 924) 	788 	(10 136)
Net insurance premium revenue 	244 	12 768 	15 104 	4 763 	– 	– 	11 521 	3 558 	1 577 	49 535 	– 	49 535
Fee income from administration businesses 	8 571 	– 	3 099 	17 	– 	– 	46 	– 	3 024 	14 757 	– 	14 757
Vitality income 	– 	– 	– 	– 	2 573 	– 	462 	238 	618 	3 891 	– 	3 891
Net banking fee and commission income 	– 	– 	– 	– 	– 	943 	– 	– 	22 	965 	– 	965
Banking fee and commission income 	– 	– 	– 	– 	– 	1 292 	– 	– 	– 	1 292 	– 	1 292
Banking fee and commission expense 	– 	– 	– 	– 	– 	(349) 	– 	– 	22 	(327) 	– 	(327)
Net bank interest and similar income 	– 	– 	– 	– 	– 	574 	– 	– 	– 	574 	– 	574
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	1 318 	– 	– 	– 	1 318 	– 	1 318
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(744) 	– 	– 	– 	(744) 	– 	(744)
Investment income earned on assets backing policyholder liabilities 	– 	8 	– 	159 	– 	– 	81 	199 	15 	462 	(462) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	(6) 	678 	10 904 	– 	(1) 	– 	– 	(1 213) 	1 839 	12 201 	2 172 	14 373
Other income 	1 395 	3 	– 	– 	1 	– 	48 	– 	97 	1 544 	– 	1 544
Finance income/(charge) on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	1 098 	– 	1 098 	(1 098) 	–
Intersegment funding 1 	– 	(492) 	492 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net income 	10 204 	12 965 	29 599 	4 939 	2 573 	1 517 	12 158 	3 880 	7 192 	85 027 	612 	85 639
Net claims and policyholders’ benefits 	(74) 	(8 182) 	(13 304) 	(2 810) 	– 	– 	(5 370) 	(973) 	(9 422) 	(40 135) 	– 	(40 135)
Claims and policyholders’ benefits 	(75) 	(11 452) 	(13 304) 	(3 153) 	– 	– 	(7 138) 	(2 514) 	(9 668) 	(47 304) 	558 	(46 746)
Insurance claims recovered from reinsurers 	1 	3 270 	– 	343 	– 	– 	1 768 	1 541 	246 	7 169 	(558) 	6 611
Acquisition costs 	(35) 	(1 833) 	(1 262) 	(784) 	(119) 	– 	(1 146) 	(2 449) 	317 	(7 311) 	1 098 	(6 213)
Expected credit losses 	– 	– 	– 	– 	– 	(139) 	– 	– 	– 	(139) 	– 	(139)
Marketing and administration expenses
– depreciation and amortisation 	(140) 	(6) 	(12) 	(64) 	(9) 	(314) 	(420) 	(49) 	(794) 	(1 808) 	(169) 	(1 977)
– derecognition of intangible assets and property and equipment 	(4) 	– 	– 	(3) 	– 	– 	(241) 	(19) 	(57) 	(324) 	– 	(324)
– impairment of intangible assets and property and equipment 	– 	– 	– 	– 	– 	– 	(45) 	– 	– 	(45) 	– 	(45)
– other expenses 	(6 097) 	(2 347) 	(1 267) 	(1 100) 	(2 429) 	(1 831) 	(4 998) 	(2 453) 	(3 937) 	(26 459) 	(100) 	(26 559)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	1 320 	2 272 	1 	3 593 	– 	3 593
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	4 412 	– 	– 	– 	– 	– 	768 	– 	5 180 	680 	5 860
– change in assets arising from reinsurance contracts 	– 	49 	– 	– 	– 	– 	61 	18 	10 	138 	(3) 	135
– change in liabilities arising from insurance contracts 	– 	(230) 	(10 868) 	(100) 	– 	– 	(226) 	(31) 	7 376 	(4 079) 	87 	(3 992)
– change in liabilities arising from reinsurance contracts 	– 	(18) 	– 	– 	– 	– 	– 	73 	– 	55 	(383) 	(328)
Fair value adjustment to liabilities under investment contracts 	– 	(3) 	(1 326) 	– 	– 	– 	– 	– 	(1 264) 	(2 593) 	(2 979) 	(5 572)
Share of net profits from equity-accounted investments 	– 	– 	– 	(16) 	– 	– 	1 	2 	574 	561 	(46) 	515
Normalised profit/(loss) from operations 	3 854 	4 807 	1 560 	62 	16 	(767) 	1 094 	1 039 	(4) 	11 661 	(1 203) 	10 458
Economic assumptions adjustments net of discretionary margins and interest rate derivatives 	– 	(2 811) 	– 	– 	– 	– 	– 	147 	– 	(2 664) 	667 	(1 997)
Economic assumptions adjustments net of discretionary margins 	– 	(2 811) 	– 	– 	– 	– 	– 	1 120 	– 	(1 691) 	(306) 	(1 997)
Fair value losses on Vitality Life interest rate derivatives 	– 	– 	– 	– 	– 	– 	– 	(973) 	– 	(973) 	973 	–
Investment income earned on shareholder investments and cash 	89 	20 	71 	– 	32 	– 	9 	28 	75 	324 	448 	772
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	– 	1 184 	1 184 	(1 184) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	122 	95 	– 	– 	– 	– 	(204) 	(3) 	10 	(10) 	–
Loss on dilution of equity-accounted investments 	– 	– 	– 	(5) 	– 	– 	– 	– 	– 	(5) 	– 	(5)
Impairment of goodwill 	– 	– 	– 	– 	– 	– 	– 	– 	(9) 	(9) 	– 	(9)
Expenses related to PAC book transfer 	– 	– 	– 	– 	– 	– 	– 	(177) 	– 	(177) 	177 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(46) 	– 	– 	– 	– 	(56) 	(102) 	46 	(56)
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(134) 	(134) 	134 	–
Finance costs 	(2) 	(1) 	– 	– 	– 	– 	(8) 	(216) 	(1 423) 	(1 650) 	(291) 	(1 941)
Intercompany finance costs 	(362) 	– 	– 	– 	– 	– 	– 	(316) 	(520) 	(1 198) 	1 198 	–
Foreign exchange gains/(losses) 	(4) 	33 	36 	– 	– 	– 	1 	– 	84 	150 	– 	150
Profit/(loss) before tax 	3 575 	2 170 	1 762 	11 	48 	(767) 	1 096 	301 	(806) 	7 390 	(18) 	7 372
Income tax expense 	(972) 	(576) 	(573) 	(21) 	4 	226 	(267) 	53 	56 	(2 070) 	18 	(2 052)
Profit/(loss) for the year 	2 603 	1 594 	1 189 	(10) 	52 	(541) 	829 	354 	(750) 	5 320 	– 	5 320
1 The intersegment funding of R492 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed
investment products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
3 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then
adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
– The Vitality Life results, for business written on the PAC licence, are reclassified to account for the contractual arrangement as a reinsurance contract
under IFRS 4 Insurance contracts
– The Unit trusts which the Group controls in terms of IFRS10 Consolidated Financial Statements are consolidated into Discovery’s results for IFRS purposes.
The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses
relating to units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
– The effects of reclassifying items to align to IFRS results.
Disclosure
for the year ended 30 June 2023

-- 16 of 50 --

18	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023	 	19
Disclosure continued
for the year ended 30 June 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.1. 	Segment information continued
R million
SA
Health
SA
Life
SA
Invest4
SA
Insure2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total 4
IFRS reporting
adjustments5
IFRS
total 4
Group 2022 Restated 4
Income statement
Insurance premium revenue 	189 	15 041 	14 029 	4 657 	– 	– 	11 299 	6 750 	7 035 	59 000 	(688) 	58 312
Reinsurance premiums 	– 	(3 523) 	– 	(103) 	– 	– 	(1 556) 	(3 600) 	(168) 	(8 950) 	688 	(8 262)
Net insurance premium revenue 	189 	11 518 	14 029 	4 554 	– 	– 	9 743 	3 150 	6 867 	50 050 	– 	50 050
Fee income from administration businesses 	7 910 	– 	2 834 	15 	– 	– 	30 	– 	1 975 	12 764 	(12) 	12 752
Vitality income 	– 	– 	– 	– 	2 338 	– 	392 	227 	538 	3 495 	– 	3 495
Net banking fee and commission income 	– 	– 	– 	– 	– 	633 	– 	– 	12 	645 	– 	645
Banking fee and commission income 	– 	– 	– 	– 	– 	853 	– 	– 	– 	853 	– 	853
Banking fee and commission expense 	– 	– 	– 	– 	– 	(220) 	– 	– 	12 	(208) 	– 	(208)
Net bank interest and similar income 	– 	– 	– 	– 	– 	318 	– 	– 	– 	318 	– 	318
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	811 	– 	– 	– 	811 	– 	811
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(493) 	– 	– 	– 	(493) 	– 	(493)
Investment income earned on assets backing policyholder liabilities 	– 	3 	– 	118 	– 	– 	9 	27 	7 	164 	(164) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	10 	485 	913 	1 	1 	– 	(52) 	(1 390) 	(1 195) 	(1 227) 	(598) 	(1 825)
Other income 	1 241 	12 	– 	– 	– 	– 	32 	– 	56 	1 341 	– 	1 341
Finance income/(charge) on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	1 368 	– 	1 368 	(1 368) 	–
Intersegment funding1 	– 	(628) 	628 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net income 	9 350 	11 390 	18 404 	4 688 	2 339 	951 	10 154 	3 382 	8 260 	68 918 	(2 142) 	66 776
Net claims and policyholders’ benefits 	(49) 	(9 222) 	(12 075) 	(3 029) 	– 	– 	(4 331) 	(877) 	(1 132) 	(30 715) 	– 	(30 715)
Claims and policyholders’ benefits 	(49) 	(14 013) 	(12 075) 	(3 151) 	– 	– 	(5 652) 	(2 231) 	(1 346) 	(38 517) 	495 	(38 022)
Insurance claims recovered from reinsurers 	– 	4 791 	– 	122 	– 	– 	1 321 	1 265 	214 	7 713 	(495) 	7 218
Recapture of reinsurance 	– 	– 	– 	– 	– 	– 	– 	89 	– 	89 	– 	89
Acquisition costs 	(27) 	(1 605) 	(1 128) 	(702) 	(111) 	– 	(963) 	(1 884) 	294 	(6 126) 	1 368 	(4 758)
Expected credit losses 	– 	– 	– 	– 	– 	(67) 	– 	– 	– 	(67) 	– 	(67)
Marketing and administration expenses
– depreciation and amortisation 	(106) 	(7) 	(11) 	(60) 	(12) 	(277) 	(458) 	(63) 	(739) 	(1 733) 	(169) 	(1 902)
– derecognition of intangible assets and property and equipment 	– 	– 	– 	(18) 	– 	– 	(1) 	(14) 	(17) 	(50) 	– 	(50)
– other expenses 	(5 568) 	(2 147) 	(1 156) 	(988) 	(2 207) 	(1 597) 	(4 091) 	(2 047) 	(3 032) 	(22 833) 	(424) 	(23 257)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	1 041 	1 818 	– 	2 859 	– 	2 859
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	5 299 	– 	– 	– 	– 	– 	3 606 	(101) 	8 804 	(3 018) 	5 786
– change in assets arising from reinsurance contracts 	– 	11 	– 	1 	– 	– 	40 	11 	1 	64 	(1) 	63
– change in liabilities arising from insurance contracts 	– 	662 	(3 050) 	(41) 	– 	– 	(65) 	(17) 	(4 488) 	(6 999) 	261 	(6 738)
– change in liabilities arising from reinsurance contracts 	– 	(351) 	– 	– 	– 	– 	– 	(3 244) 	– 	(3 595) 	3 018 	(577)
Fair value adjustment to liabilities under investment contracts 	– 	(2) 	220 	– 	– 	– 	– 	– 	42 	260 	(228) 	32
Share of net profits from equity-accounted investments 	– 	– 	– 	(13) 	– 	– 	2 	– 	474 	463 	(41) 	422
Reversal of impairment of equity-accounted investment 	– 	– 	– 	– 	– 	– 	– 	– 	134 	134 	– 	134
Normalised profit/(loss) from operations 	3 600 	4 028 	1 204 	(162) 	9 	(990) 	1 328 	671 	(304) 	9 384 	(1 376) 	8 008
Economic assumptions adjustments net of discretionary margins and interest rate derivatives 	– 	(651) 	– 	– 	– 	– 	– 	567 	– 	(84) 	253 	169
Economic assumptions adjustments net of discretionary margins 	– 	(651) 	– 	– 	– 	– 	– 	820 	– 	169 	– 	169
Fair value losses on VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	– 	(253) 	– 	(253) 	253 	–
Investment income earned on shareholder investments and cash 	37 	11 	38 	– 	28 	– 	– 	8 	18 	140 	156 	296
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	5 	913 	918 	(918) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	51 	27 	– 	– 	– 	– 	(454) 	(1) 	(377) 	377 	–
Gains from dilution of equity-accounted investments 	– 	– 	– 	19 	– 	– 	– 	– 	14 	33 	– 	33
Expenses related to PAC book transfer 	– 	– 	– 	– 	– 	– 	– 	(182) 	– 	(182) 	182 	–
Covid-19 vaccination programme 	– 	– 	– 	– 	– 	– 	– 	– 	(157) 	(157) 	157 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(41) 	– 	– 	– 	– 	(59) 	(100) 	41 	(59)
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(158) 	(158) 	158 	–
Finance costs3 	(1) 	25 	– 	– 	– 	– 	(6) 	(104) 	(1 290) 	(1 376) 	(282) 	(1 658)
Intercompany finance costs 	(297) 	– 	– 	– 	– 	– 	(4) 	(230) 	(396) 	(927) 	927 	–
Foreign exchange gains 	4 	25 	37 	– 	– 	– 	– 	– 	89 	155 	– 	155
Profit/(loss) before tax 	3 343 	3 489 	1 306 	(184) 	37 	(990) 	1 318 	281 	(1 331) 	7 269 	(325) 	6 944
Income tax expense 	(951) 	(718) 	(438) 	43 	(30) 	218 	(285) 	224 	147 	(1 790) 	325 	(1 465)
Profit/(loss) for the year 	2 392 	2 771 	868 	(141) 	7 	(772) 	1 033 	505 	(1 184) 	5 479 	– 	5 479
1 The intersegment funding of R628 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed
investment products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
3 Finance costs in Discovery Life includes a reversal of interest payable to the South African Revenue Services provided for in the prior year.
4 The comparative information has been restated. Refer to note A.6. for detail.
5 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then
adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
– The Vitality Life results, for business written on the PAC licence, are reclassified to account for the contractual arrangement as a reinsurance contract
under IFRS 4 Insurance contracts.
– The Unit trusts which the Group controls in terms of IFRS10 Consolidated Financial Statements are consolidated into Discovery’s results for IFRS purposes. The
IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses relating to
units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
– The effects of reclassifying items to align to IFRS results.

-- 17 of 50 --

20	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.2. 	Normalised profit from operations
The following table shows the main components of the normalised profit from operations for the year ended 30 June 2023:
R million
Group
2023
Group
2022
%
Change
Discovery Health 	3 854 	3 600 	7
Discovery Life 	4 807 	4 028 	19
Discovery Invest 	1 560 	1 204 	30
Discovery Insure-Personal lines 	62 	(162) 	(138)
Discovery Vitality 	16 	9 	78
Discovery Bank 	(767) 	(990) 	(23)
Other initiatives and central costs 	(436) 	(232) 	88
– SA new initiatives1 	(312) 	(244) 	28
– Central costs 	(124) 	12
Normalised profit from South Africa composite 	9 096 	7 457 	22
VitalityHealth 2 	1 283 	1 328 	(3)
VitalityLife 	1 039 	671 	55
Closure costs of VitalityInvest and VitalityCar in run down3 	(455) 	(458) 	(1)
Other initiatives and central costs 	(79) 	(60) 	32
Normalised profit from United Kingdom composite 	1 788 	1 481 	21
Vitality Health International – Ping An Health Insurance 	596 	338 	76
Vitality Health International – Other4 	(195) 	(193) 	1
VitalityNetwork4 	411 	325 	26
Other initiatives and central costs 	(35) 	(24) 	46
Normalised profit from Vitality Global composite 	777 	446 	74
Normalised profit from operations 5 	11 661 	9 384 	24
1 SA new initiatives comprise Discovery Business Insurance, Umbrella Funds and Africa Health.
2 The difference between VitalityHealth normalised profit compared to that shown in the segment information is the accelerated write-off in the
current year of the VitalityCar’s capitalised systems and intangible assets, with a pre-tax impact of R189 million. The write-off is disclosed in this
table in Closure costs of VitalityInvest and VitalityCar in run down (see below).
3 Closure costs include:
– VitalityInvest R266 million (30 June 2022: R458 million)
– VitalityCar R189 million (30 June 2022: nil).
4 New initiatives and head office costs incurred in the Vitality Global composite have been allocated to Vitality Network and Vitality Health International
– Other and totalled R215 million for the year ended 30 June 2023 (30 June 2022: R341 million).
5 Normalised profit from operations is, consistent with prior years, presented excluding the impact resulting from economic assumption changes
in the long-term insurance businesses. Refer note B.3.
Disclosure continued
for the year ended 30 June 2023

-- 18 of 50 --

A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.3. 	Earnings, headline earnings and normalised headline earnings
Group
2023
Group
2022
Number of shares used in calculation
Weighted average number of shares in issue (‘000) 	658 045 	656 901
Diluted weighted number of shares (‘000) 	661 328 	663 082
Earnings per share (cents):
– basic 	785.4 	825.5
– diluted 	781.5 	817.8
Headline earnings per share (cents):
– basic 	834.3 	792.4
– diluted 	830.1 	785.0
Normalised headline earnings per share (cents):
– basic 	1 166.7 	885.5
– diluted 	1 160.9 	877.3
Weighted average number of shares
Group
2023
Group
2022
Issued ordinary shares at 1 July 	656 957 	658 805
Effect of treasury shares vested 	1 052 	–
Effect of share options exercised and vesting of share awards 	36 	96
Weighted average number of ordinary shares at 30 June (basic) 	658 045 	656 901
Effect of share options exercised and vesting of shares awards 	3 283 	6 181
Weighted average number of ordinary shares at 30 June (diluted) 	661 328 	663 082
Earnings reconciliation
R million
Group
2023
Group
2022
Profit attributable to ordinary shareholders 	5 258 	5 422
Adjusted for:
– Profit attributable to non-forfeitable dividend share plan 	(90) 	–
Profit attributable to ordinary shareholders of the Company (basic) 	5 168 	5 422
21

-- 19 of 50 --

22	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Disclosure continued
for the year ended 30 June 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.3. 	Earnings, headline earnings and normalised headline earnings continued
Headline earnings reconciliation
Headline earnings per share is disclosed per the JSE Limited Listings Requirements and is calculated in accordance with the circular
titled “Headline Earnings” issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit
after tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary
shares in issue.
Group 2023 	Group 2022
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Profit attributable to the ordinary shareholders 	5 168 	5 422
Adjusted for:
– Gain on disposal of intangible assets 	– 	– 	– 	(131) 	29 	(102)
– Loss on derecognition of intangible assets 	290 	(60) 	230 	37 	(5) 	32
– Loss on derecognition of property and equipment 	34 	(7) 	27 	13 	(1) 	12
– Loss on disposal of property and equipment 	8 	(1) 	7 	3 	– 	3
– Impairment of goodwill 	9 	– 	9 	– 	– 	–
– Impairment of property and equipment 	45 	– 	45 	– 	– 	–
Adjustments attributable to equity-accounted investments:
– Loss/(gain) on dilution and disposal of equity-accounted
investments 	5 	(1) 	4 	(33) 	4 	(29)
– Reversal of impairment of equity-accounted investments 	– 	– 	– 	(134) 	– 	(134)
Headline earnings (basic and diluted) 	5 490 	5 204
Normalised headline earnings reconciliation
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies at the end of the results
announcement. Management considers that Normalised headline earnings is an appropriate alternative performance measure to
enhance the comparability and understanding of the financial performance of the Group.
Group 2023 	Group 2022
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Headline earnings 	5 490 	5 204
Adjusted for:
– Economic assumption adjustments net of discretionary
margins and interest rate derivatives 	2 664 	(728) 	1 936 	84 	(74) 	10
– Loss/(gain) on economic assumption adjustments
net of discretionary margins 	1 691 	(529) 	1 162 	(169) 	(26) 	(195)
– Loss on fair value changes on VitalityLife interest rate
derivative 	973 	(199) 	774 	253 	(48) 	205
– Loss on fair value changes in the time value of swaption
contract in VitalityLife 	204 	(42) 	162 	454 	(87) 	367
– Other 	102 	(12) 	90 	233 	2 	235
– Amortisation of intangible assets arising from business
combinations 	56 	(12) 	44 	59 	(13) 	46
– Gain on disposal of intangible assets 	– 	– 	– 	131 	(29) 	102
– Recognition of deferred tax assets on assessed losses not
recognised in previous periods 	– 	– 	– 	– 	(14) 	(14)
– Loss on fair value changes on foreign exchange contracts
not designated as hedges 	– 	– 	– 	2 	(1) 	1
– Increase or decrease in deferred tax balances resulting from
use of different tax rates on items that were excluded from
normalised headline earnings 	– 	– 	– 	– 	59 	59
Adjustments attributable to equity-accounted investments
– Amortisation of intangible assets arising from business
combinations 	46 	– 	46 	41 	– 	41
Normalised headline earnings (basic and diluted) 	7 678 	5 816

-- 20 of 50 --

23
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.4. 	Revenue from non-insurance activities
Discovery Group’s Revenue includes ‘Fee income from administration business’, ‘Vitality Income’ and ‘Banking fee and commission
income’.
The split of revenue per geographical region and reportable segment can be viewed in Note A.1. Segment information.
The split of revenue according to the timing of satisfaction of performance obligations, i.e. ‘over time’ or a ‘point-in-time’ is as follows:
R million
Group
2023
Group
2022
Fee income from administration business: Health income 	11 959 	10 971
– Over time 	11 932 	10 548
– Point-in-time 	27 	423
Fee income from administration business: Intellectual Property fees 	2 798 	1 781
– Over time 	2 798 	1 781
Vitality Income 	3 891 	3 495
– Over time 	2 660 	2 348
– Point-in-time 	1 231 	1 147
Banking fee and commission income 	1 292 	853
– Over time 	687 	389
– Point-in-time 	605 	464
A.5. 	Borrowings
R million 	Reference
Group
2023
Group
2022
Borrowing from banks and listed debt 	16 328 	16 308
– United Kingdom borrowings 	A.5.1 	3 682 	3 122
– South African borrowings 	A.5.2 	12 646 	13 186
Bank overdraft in underlying liabilities of consolidated Unit Trusts 	33 	156
Lease liabilities 	4 225 	4 120
– 1 Discovery Place 	3 326 	3 373
– Other lease liabilities 	899 	747
Total borrowings at amortised cost 	20 586 	20 584
A.5.1 United Kingdom borrowings
Carrying value GBP/Rand million
Facility amount
GBP million 	Variable rate 	Capital repayment and maturity date
Group 2023 	Group 2022
GBP 	R 	GBP 	R
25 	SONIA + 2.75% 1 	At maturity – 23 December 20252 	25 	597 	– 	–
75 	SONIA + 3.00%1 	At maturity – 21 December 20242,3 	75 	1 793 	– 	–
55 	SONIA + 2.85%1 	At maturity – 12 December 20254 	54 	1 292 	– 	–
100 	SONIA + 2.38%1 	At maturity – 31 July 20232 	– 	– 	100 	1 999
80 	SONIA + 2.73%1 	Instalments 31 July 20234 	– 	– 	42 	847
34 	SONIA + 1.31%1 	At maturity – 19 October 20224 	– 	– 	14 	276
Total UK borrowings 	154 	3 682 	156 	3 122
1 Interest payable quarterly in arrears.
2 The £100 million facility drawn down at 30 June 2022, was refinanced in December 2022.
3 1 year extension option available at discretion of lender.
4 The £80 and £30 million facilities, of which £56 million was drawn down at 30 June 2022 in total, was refinanced in December 2022.
Total finance costs in respect of the UK borrowings for the year ended 30 June 2023 was £10.1 million (R216 million) (30 June
2022: £2.9 million (R59 million)).

-- 21 of 50 --

24	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Disclosure continued
for the year ended 30 June 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.5. 	Borrowings continued
A.5.2 South African borrowings
CREDIT RATING
In January 2023 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s global-scale long-term issuer rating of Ba3 and
the national-scale long-term issuer rating at A1.za. The outlook was unchanged as stable, aligned to the outlook of the country.
A5.2.1 DISCOVERY LIMITED
Carrying value R million
Facility amount
R million 	Variable rate
Interest rate
per annum 	Capital repayment and maturity date
Group
2023
Group
2022
Listed DMTN 4
500 	3-month Jibar + 161 bps 	8.10% 1,3 	At maturity – 21 November 2022 	– 	503
500 	3-month Jibar + 205 bps 	4.25%1,3 	At maturity – 21 August 2023 	505 	503
200 	- 	10.46%2 	At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191 bps 	8.40%1,3 	At maturity – 21 November 2024 	808 	805
1 200 	3-month Jibar + 191 bps 	7.30% 1,3 	At maturity – 21 November 2024 	1 218 	1 217
700 	3-month Jibar + 180 bps 	8.49%1,3 	At maturity – 21 August 2026 	707 	704
300 	3-month Jibar + 180 bps 	7.60%1,3 	At maturity – 21 August 2026 	304 	303
792 	3-month Jibar + 173 bps 	7.98%1,3 	At maturity – 21 May 2027 	799 	792
226 	3-month Jibar + 180 bps 	7.98%1,3 	At maturity – 21 May 2029 	228 	226
Unlisted DMTN4,5
1 100 	– 	8.92%3 	At maturity – 10 March 2023 	– 	1 104
2 500 	– 	9.62%3 	At maturity – 22 February 2025 	2 522 	2 520
1 650 	– 	9.55%3 	At maturity – 10 March 2026 	1 658 	–
Other
1 000 	3-month Jibar + 245 bps 	7.83%1,3 	At maturity – 2 March 2023 	– 	1 003
1 000 	3-month Jibar + 190 bps 	– 	At maturity – 2 March 2028 	997 	–
1 400 	3-month Jibar + 125 bps 	– 	At maturity – 12 October 2022 	– 	702
Total Discovery Limited borrowings 	9 948 	10 584
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest is payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN
notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market
on an ongoing basis.
A5.2.2 DISCOVERY CENTRAL SERVICES
Carrying value R million
Facility amount
R million 	Interest rate per annum 	Capital repayment and maturity date
Group
2023
Group
2022
1 400 	3-month Jibar + 2.05% 1,2 	Instalments – 29 October 2027 	1 408 	1 417
650 	11.56%3 	At maturity – 29 October 2027 	445 	494
691 	3-month Jibar + 1.9% 	At maturity – 30 June 2027 	694 	691
1 500 	3-month Jibar + 1.45% 	At maturity – 8 June 2024 	151 	–
Total Discovery Central Services borrowings 	2 698 	2 602
1 Interest payable quarterly in arrears.
2 During the financial year, the rate was renegotiated from a fixed rate of 10.60%, to a floating interest rate.
3 Instalments of interest and capital is monthly.
Total finance costs in respect of South African borrowings and related hedges for the year ended 30 June 2023 was R1 225 million
(30 June 2022: R932 million).

-- 22 of 50 --

25
A.6. 	Restatement as a result of prior period error – reclassification of unit-linked insurance
contracts to unit-linked investment contracts
During the IFRS 17 project, Discovery performed a full reassessment of all its insurance contracts to ensure the products were
correctly included in the scope of the IFRS 17 project. This full assessment and evaluation was necessary to determine whether the
contracts transfer significant insurance risk, a prerequisite for the contract to be recognised under IFRS 17.
During the year, Discovery identified that certain offshore unit-linked policies do not transfer significant insurance risk as required
under IFRS 17. Instead of being classified as unit-linked insurance contracts, these policies should have been accounted for as
unit-linked investment contracts under IFRS 9 Financial Instruments.
Discovery noted that the definition of significant insurance risk under IFRS 17 and IFRS 4 is the same. Accordingly, the change in
treatment did not constitute a change because of the transition to IFRS 17. Instead, a correction would be required under IFRS 4 of
the previously published information. The error was rectified as a reclassification from IFRS 4 to IFRS 9.
Accordingly, as disclosed in the Annual Financial Statements, these policies were reclassified from unit-linked insurance contracts
as disclosed in Note 18 ‘Liabilities arising from insurance contracts’ to Note 21 ‘Investment contracts at fair value through profit
or loss’ which includes unit-linked investment products. The unit priced component of the fair value measurement of the
policyholder liability remained unchanged. The negative rand reserve that was previously recognised under IFRS 4 was
derecognised. The incremental costs to obtain the contracts have also been recognised accordingly in Note 9A ‘Assets arising from
contracts with customers and contract liabilities’.
The change in presentation of the unit-linked policies also affected the Group income statement but did not affect the previously
reported earnings.
The tables below summarise the restatement’s impact on the Group statement of financial position and the Group income statement.
Statement of financial position
R million
Group
30 June 2021
(previously
reported) 	Correction
Group
1 July 2021
(as restated)
Assets arising from contracts with customers 	1 248 	127 	1 375
Liabilities arising from insurance contracts 	(100 977) 	936 	(100 041)
Investment contracts at fair value through profit or loss 	(32 291) 	(1 063) 	(33 354)
Statement of financial position
R million
Group
30 June 2022
(previously
reported) 	Correction
Group
30 June 2022
(as restated)
Assets arising from contracts with customers 	1 549 	143 	1 692
Liabilities arising from insurance contracts 	(109 200) 	1 133 	(108 067)
Investment contracts at fair value through profit or loss 	(37 361) 	(1 276) 	(38 637)
Income statement
R million
Group
30 June 2022
(previously
Reported) 	Correction
Group
30 June 2022
(as restated)
Insurance premium revenue 	58 782 	(470) 	58 312
Claims and policyholders’ benefits 	(38 207) 	185 	(38 022)
Acquisition cost 	(4 774) 	16 	(4 758)
Net transfer to/from assets and liabilities under insurance contracts 	(6 935) 	197 	(6 738)
Fair value adjustment to liabilities under investment contracts 	(40) 	72 	32
Profit from operations 	7 858 	– 	7 858
The restatement has had no change to operating, investing, and financing cash flows and no changes to the Statement of Changes in
Equity. There is no impact on Discovery’s Profit from operations; consequently, basic or diluted earnings per share remain unchanged.

-- 23 of 50 --

26	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.7. 	Fair value hierarchy of financial instruments
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three
levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or
regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data. Instruments
in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable
market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than observable
market data and where at least one input (which could have a significant effect on instruments’ valuation) cannot be based on
observable market data.
R million
Group 2023
Level 1 	Level 2 	Level 3 	Total
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	50 204 	6 321 	– 	56 525
– Debt portfolios 	40 852 	1 721 	– 	42 573
– Money market portfolios 	– 	22 656 	– 	22 656
– Multi-asset portfolio 	– 	33 672 	– 	33 672
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	59 	– 	59
– not designated as hedging instruments 	– 	60 	– 	60
Total financial assets 	91 056 	64 489 	– 	155 545
Financial liabilities
Investment contracts at fair value through profit or loss 	– 	48 044 	– 	48 044
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	1 	– 	1
– not designated as hedging instruments 	– 	19 	– 	19
Total financial liabilities 	– 	48 064 	– 	48 064
There were no transfers between level 1 and 2 during the current financial period.
Disclosure continued
for the year ended 30 June 2023

-- 24 of 50 --

27
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.7. 	Fair value hierarchy of financial instruments continued
Group 2022
R million 	Level 1
Restated 1
Level 2 	Level 3
Restated 1
Total
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	54 271 	3 677 	– 	57 948
– Debt portfolios 	46 672 	920 	– 	47 592
– Money market portfolios 	– 	14 680 	– 	14 680
– Multi-asset portfolios 	– 	21 274 	– 	21 274
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	17 	– 	17
– not designated as hedging instruments 	– 	259 	– 	259
Total financial assets 	100 943 	40 827 	– 	141 770
Non-financial assets
Non-current assets held for sale 	– 	– 	171 	171
Total non-financial assets 	– 	– 	171 	171
Financial liabilities
Investment contracts at fair value through profit or loss 	– 	38 637 	– 	38 637
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	56 	– 	56
– not designated as hedging instruments 	– 	146 	– 	146
Total financial liabilities 	– 	38 839 	– 	38 839
1 The comparative information has been restated. Refer to note A.6. for detail.
Specific valuation techniques used to value financial instruments in level 2
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of
recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the same,
discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices
obtained in actual market transactions.

-- 25 of 50 --

28	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Disclosure continued
for the year ended 30 June 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.7. 	Fair value hierarchy of financial instruments continued
Valuation techniques used in determining the fair value of assets and liabilities:
Instruments 	Valuation technique 	Main inputs and assumptions
Within equity
portfolios,
Equity-linked
notes
The calculation of the daily value of the equity linked investments is
made by the provider of the note. Discovery has procedures in place
to ensure that these prices are correct. Aside from the daily
reasonableness checks versus similar funds and movement since
the prior day’s price, the fund values are calculated with reference
to a specific formula or index, disclosed to the policyholders, which
is recalculated by Discovery in order to check if the price provided
by the provider is correct.
For level 2 fair value hierarchy
items:
– discount rate
– spot price of the underlying
Multi-assets 	The fair values of third-party financial liabilities arising on the
consolidation of mutual funds are determined using the quoted put
(exit) price provided by the fund manager and discounted for the
applicable notice period. The fair value of a financial liability with a
demand feature is not less than the amount payable on demand,
discounted from the first date on which the amount could be
required to be paid.
For level 2 fair value hierarchy
items:
– discount rate
Debt portfolios
and Money
market
instruments
Money market instruments are valued by discounting the future
cash flows using a risk-adjusted discount rate.
For level 2 fair value hierarchy
items:
– discount rate, credit spread
Investment
contracts at fair
value through
profit or loss
Unit-linked policies: assets which are linked to the investment
contract liabilities are owned by the Group. The investment contract
obliges the Group to use these assets to settle these liabilities.
Therefore, the fair value of investment contract liabilities is
determined with reference to the fair value of the underlying assets
(i.e. amount payable on surrender of the policies).
Annuity: certain discounted cash flow models are used to determine
the fair value of the stream of future payments.
For level 2 fair value hierarchy
items:
– discount rate
– spot price of underlying
Derivatives 	Standard derivative contracts are valued using market accepted
models and quoted parameter inputs. More complex derivative
contracts are modelled using more sophisticated modelling
techniques applicable to the instrument. Techniques include:
 Discounted cash flow model
 Black-Scholes model
 Combination technique models
For level 2 fair value hierarchy
items:
– discount rate
– spot price of the underlying
– correlation factors
– volatilities
– earnings yield
– valuation multiples
A.8. 	Cash generated by operations
The Group Statement of cash flows includes flows related to shareholders and policyholders. As a result, the cash generated by
operations in the current year is distorted by policyholder withdrawals as VitalityInvest is wound down. In addition, working capital
changes include R3 788 million return of inward collateral and increase in outward collateral related to the interest rate hedge
structures and deposit back in the UK.

-- 26 of 50 --

29
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS
B.1. 	Exchange rates to South African Rand used in the preparation of these results
Closing 	Average
Exchange Rates 	Group 2023 	Group 2022 	Change % 	Group 2023 	Group 2022 	Change %
US dollar 	18.87 	16.47 	(14.57) 	17.79 	15.22 	(16.89)
Pound sterling 	23.99 	20.00 	(19.95) 	21.43 	20.25 	(5.83)
Chinese Yuan 	2.60 	2.46 	(5.69) 	2.55 	2.35 	(8.51)
B.2. 	Capital management, financial leverage ratio and covenants
The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the consolidated Statement of
financial position. The Group’s objectives when managing capital are:
 To comply with the statutory capital requirements required by the regulators of the insurance markets in which the Group
operates;
 To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory;
requirements in the event of deviations from the main assumptions affecting the Group’s insurance businesses;
 To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements;
 To achieve an optimal and efficient capital funding profile; and
 To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and
subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the
Group.
A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new shares,
debt, reinsurance arrangements and other hybrid instruments.
Financial leverage ratio
As part of the capital management process, the Group monitors its capital structure utilising various measures, one of which is the
Financial Leverage Ratio (FLR). This ratio is calculated as total debt1 divided by total debt plus total equity. The Group’s strategy is to
maintain a prudent FLR of 28.0% per the Group Risk Appetite statement. However, the 28.0% measure is merely a risk appetite
indicator and does not necessarily indicate any form of a breach in terms of regulatory or covenant restrictions. The table below
summarises the FLR position as at the end of the reporting period.
R million
Group
2023
Group
2022
– Borrowings at amortised cost1 	16 361 	16 464
– Guaranteed deposit facilities 	– 	300
Total debt and guarantees1 	16 361 	16 764
Total equity 	63 974 	53 555
Financial leverage ratio % 	20.4% 	23.8%
1 Excluding all IFRS 16 lease liabilities of R4 225 million (June 2022: R4 120 million).
The FLR at 30 June 2023 is within Discovery’s risk appetite.

-- 27 of 50 --

30	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
B.2. 	Capital management, financial leverage ratio and covenants continued
Regulatory capital
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum
amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum
required capital must be maintained at all times throughout the period.
Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential
Standards, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime.
The table below summaries the capital requirements on the statutory basis, across the Group subsidiaries, and the actual solvency
capital held in relation to these requirements as at the end of the reporting year.
Group 2023 	Group 2022
Statutory capital requirements 	Cover 	Statutory capital requirements 	Cover
Discovery Life 	R20 809 million 	1.9 times 	R20 322 million 	1.7 times
Discovery Insure 	R1 113 million 	1.6 times 	R1 138 million 	1.2 times
VitalityHealth 	£130.8 million 	£117.2 million
(R3 138 million) 	1.4 times 	(R2 344 million) 	1.5 times
VitalityLife 	£272.1 million 	£297.1 million
(R6 528 million) 	2.1 times 	(R5 943 million) 	2.1 times
Debt covenants
As per JSE Limited Listings and Debt Listings disclosure requirements, the following are the key debt covenant ratios and their
proximity to minimum requirements as per the contractual financial covenants.
Debt covenant 	Minimum requirement
Group
2023
Group
2022
Group Debt1 to EBITDA Ratio2 	Less than 2.5 times 	1.3 	1.8 times
Group financial indebtedness to embedded value
– Group financial indebtedness is as per Group
Debt in the calculation above
Less than 30% of Group
Embedded value
17.6% 	20.3%
Discovery Life Statutory Capital Requirement
(SCR)
SCR cover must be more than
1.1 times
1.9 	1.7 times
Group embedded value 	Greater than R30 billion 	R98 176 million 	R86 258 million
New business embedded value must not be
negative
Positive value of new business for
3 consecutive 6-month periods
June 2023:
R463 million
December 2022:
R940 million
June 2022:
R1 124 million
June 2022:
R1 124 million
December 2021:
R937 million
June 2021:
R946 million
1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the
1 Discovery Place (1 DP) lease and includes guarantees issued to third parties.
2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1DP and excludes items deemed
extraordinary, such as economic assumption adjustments, and specified FinRe arrangements.
Disclosure continued
for the year ended 30 June 2023

-- 28 of 50 --

31
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
B.3. 	Impact of long-term interest rates in the SA and UK markets
The long-term insurance businesses in SA and the UK are exposed to long-term nominal and real interest rates given the impact of
rates on the long-term assumptions applicable to valuation of insurance contracts. The period under review was characterised
by aggressive global monetary policy tightening by central banks following sustained inflationary pressure, resulting in rapidly
increasing global bond yields. In South Africa, economic and political pressures further contributed to increasing SA bond yields. For
Discovery Life, this impact of higher long-term interest rates manifests mainly as a lower discounted value of future cash flows and
therefore a lower valuation of those contracts. For VitalityLife whole of life business, higher long-term rates will mainly manifest as
higher expected investment returns resulting in lower costs to fulfil future insurance contracts and a positive impact on the
valuation (before hedging). As noted with previous results announcements, the actual cash flows themselves are not materially
affected nor would it have material negative solvency or liquidity consequences.
Given the volatility of these impacts on results and given that it has little or no bearing on underlying operating performance of these
businesses, consistent with prior years, Discovery has excluded these effects, net of tax, in the presentation of normalised earnings
measures. This treatment in the presentation of normalised measures is consistent with prior years and also largely consistent with
the available election under the soon to be adopted new accounting standard for insurance contracts (IFRS17) to isolate such economic
impacts in other comprehensive income (OCI).
Discovery Life SA – impact of economic assumptions
The impact of the economic assumptions on profit or loss, was a net loss in SA Life of R2 811 million (2022: R651 million). The loss
for the year ended 30 June 2023 was driven by the changes in both the South African nominal and real yield curves as well as
nominal and real yield curve changes on dollar denominated business.
Vitality Life UK – impact of economic assumptions net of interest rate risk
mitigation strategy
During the year ended 30 June 2023 the interest rate risk mitigation strategy proved to be effective despite the extreme volatility
in the UK bond markets following political changes and rising levels of inflation in the early part of the financial year.
The net gain within the UK Life Segment of £6.8 million (R147 million) (2022: net gain £28 million (R567 million)) consisted of:
 economic assumption gains amounting to £52.2 million (R1 120 million) (2022: gain £40.5 million (R820 million))
 less net fair value losses on interest rate derivatives (including fair value losses on the swap contracts and intrinsic value gains
of the swaption contract) of £45.4 million (R973 million) (2022: losses £12.5 million (R253 million)).
Against this should be seen the net fair value write-off of the time value of the swaption contract of £9.5 million (R204 million)
(2022: £22.4 million (R454 million)).
On this basis, the effective net loss recognised in profit or loss resulting from economic assumptions, including all hedge impacts
amounts to £2.7 million (R57 million) (2022: net gain of £5.6 million (R113 million)) while a component of the gain for the year ended
30 June 2023 of £25.5 million (R546 million) was recognised directly to discretionary margins in line with the Group’s accounting
policy (refer below).
Per Discovery’s accounting policy, where insurance contracts are backed by assets, other than negative reserves, changes in economic
assumptions are recognised directly in profit or loss. Furthermore, positive changes in economic assumptions are first recognised
separately in profit or loss to the extent that it reverses related losses previously recognised in profit or loss. Thereafter, positive
changes in economic assumptions increase discretionary margins.

-- 29 of 50 --

32	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
B.3. 	Impact of long-term interest rates in the SA and UK markets continued
Change in future hedge strategy – VitalityLife business
The introduction of IFRS 17 enables VitalityLife to make use of OCI election to remove the volatility of reported financial performance
arising from short-term changes in economic assumptions and present a more reflective performance of the business over the long
term. Given this change, several of the VitalityLife swaps were exited shortly before the end of the year under review. In addition,
the swaption purchased in June 2022 for a premium of £14.1 million was sold in June 2023 for £33.8 million (R724 million), realising
a gain of £19.7 million (R422 million).
VitalityLife continues to hold interest rate swaps and total returns swaps (“TRS”) to manage the interest rate risk on the legacy PAC
book of business. No swaptions are held at 30 June 2023 as the business is now able to manage any remaining risk within its risk
appetite without the need for incurring the ongoing costs of purchasing swaptions.
The impact of these derivative instruments is reflected in the overall £6.8 million (R147 million) gain from the impact of economic
assumptions net of interest rate risk mitigation as well as the increase in discretionary margins by £25.5 million (R546 million).
B.4. 	VitalityLife UK-impact of inflation rates
VitalityLife’s result includes positive operating experience variances over the year, most notably the benefit of significantly improved
premium indexation in the higher inflationary environment. This benefit is a combination of a multi-year focus on continuous
improvement of the quality of the portfolio, including an increase in the proportion of index-linked policies as well as prior
implementation of persistency initiatives. Actual premium and benefit inflation over the period was higher than expectation, with a
weighted average of 9.6% compared to best estimate assumption of 3.5%. In terms of Discovery’s accounting policy, these net
positive impacts are first recognised in profit or loss to the extent that it reverses losses previously recognised. Thereafter, the
impact of positive changes increases discretionary margins. This resulted in an exceptional net favourable impact of £18.3 million
(R392 million) over the year (after taking into account the impact of indexation holidays and cancellations, other negative
variances and assumption changes).
B.5. 	VitalityCar
The UK car insurance market has experienced unprecedented claims inflation leading to significant price increases, which the
underwriter has had to pass on to VitalityCar members. These increases have materially impacted VitalityCar’s ability to deliver value
for good drivers and has led to the decision to not offer members cover beyond their current plan year and run off the book by
30 June 2024. This has resulted in an accelerated write-off of the business’s capitalised systems and intangible assets, with a pre-tax
impact of £8.8 million (R189 million). This write-off as well as the operating loss incurred by VitalityCar is included in the VitalityHealth
segment. The write-off is included in Closure costs of VitalityInvest and VitalityCar in run down in the components of Normalised
profit from operations. Refer A.2.
B.6. 	VitalityInvest
In the previous financial year, a strategic review of new initiatives led to a decision to change the strategy with regard to VitalityInvest
in the UK. The decision, as previously announced, was taken to exit the UK investment market given the structural change in market
conditions, mainly driven by significant margin compression.
The careful management of the transfer and wind-down took longer than expected, but should be completed by 31 December 2023.
This impacted the income statement for the year ended 30 June 2023, compared to the prior year as follows:
R million
Group
2023
Group
2022
Insurance premium revenue 	1 218 	6 665
Claims and policyholders’ benefits 	(9 230) 	(1 024)
Marketing and administration expenses 	(283) 	(390)
Change in liabilities arising from insurance contracts 	7 415 	(4 488)
Other 	614 	(1 221)
Normalised loss from operations
(included in Closure costs of VitalityInvest and VitalityCar in run down. Refer A.2.) 	(266) 	(458)
There are large changes to the insurance premium revenue, claims and policyholders’ benefits and changes in liabilities arising
from insurance contracts which are all related and offsetting each other. These are reflecting the large reduction in funds under
management as the VitalityInvest unit-linked reserves are passed to other providers.
Disclosure continued
for the year ended 30 June 2023

-- 30 of 50 --

33
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
B.7. 	Consolidation of Discovery Unit Trusts
Unit trusts which the Group controls in terms of IFRS 10 are consolidated into Discovery’s results for accounting purposes, which
results in the recognition of the underlying assets and liabilities of each of the funds.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders.
Assets and liabilities of these Discovery Unit Trusts however increased by R3 654 million, compared to the prior financial year ended
30 June 2022, with movements in the following line items on the Group’s Statement of financial position:
R million
Group
2023
Group
2022 	Movements
Investments at fair value through profit or loss 	25 439 	22 128 	3 311
Insurance receivables, contract receivables and other receivables 	643 	770 	(127)
Cash and cash equivalents 	2 435 	1 943 	492
Other assets 	– 	22 	(22)
Total change in assets 	28 517 	24 863 	3 654
Investment contracts at fair value through profit or loss 	28 346 	24 320 	4 026
Borrowings at amortised costs (bank overdraft) 	33 	156 	(123)
Other payables 	482 	512 	(30)
Other liabilities 	(344) 	(125) 	(219)
Total change in liabilities 	28 517 	24 863 	3 654
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The cash flow impact of the movement in
policyholder investments for the year is included in the following line items on the Group’s Statement of cash flows:
 Purchase of investments held to back policyholder liabilities includes cash outflows of R35 177 million (2022: R30 009 million).
 Proceeds from the disposal of investments held to back policyholder liabilities includes cash inflows of R32 073 million
(2022: R29 661 million).
B.8. 	Material transactions with related parties
Discovery Long-term Incentive Plan Trust
At the annual general meeting held on 28 November 2019, the shareholders approved the establishment of the Discovery Long-
term Incentive Plan Trust (Trust) with the purpose, inter alia, to subscribe, purchase and/or otherwise acquire and hold Discovery
ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with the
requirements of the Trust. During December 2022, 4 182 946 (2021: 3 194 870) new shares were issued by Discovery Limited to the
Trust at a value of R514 million (2021: R443 million). In addition, during the year ended 30 June 2023, shares of 1 402 275 vested
with participants. In terms of IFRS, while held in the Trust, these shares are treated as treasury shares and not treated as issued, for
accounting purposes.
B.9. 	Major customers and other Discovery entities not part of Discovery group
Discovery Health Medical Scheme (DHMS)
Discovery Health administers DHMS and provides managed care services for which it charges an administration fee and a managed
healthcare fee respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totalled
R7 414 million for the year ended 30 June 2023 (2022: R6 804 million). Discovery offers the members of DHMS access to the Vitality
programme.

-- 31 of 50 --

34	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
B.10. Changes in directorate
Changes to the Board of Discovery Limited from 1 July 2022 to the date of this announcement are as follows:
 HL Bosman, a non-executive director, retired from the Board, effective 1 December 2022. This follows the unbundling by
Rand Merchant Investment Holdings Limited of its shareholding in Discovery Limited earlier in 2022. He has served as a non-
executive director of the Company since 2014 and has served as the former chairperson and member of the Risk and
Compliance Committee and as a member of the Remuneration Committee and the Nominations Committee. He has also
retired as a non-executive director of Discovery Life Limited, Discovery Health (Pty) Limited and Discovery Vitality (Pty) Limited.
 HD Kallner, NS Koopowitz, Dr A Ntsaluba and A Pollard stepped down as executive directors of the Board of Discovery
Limited, effective 1 March 2023. This is aligned with the Group’s organisation around the three distinct composites, Discovery
in South Africa, Vitality in the United Kingdom and Vitality Global resulting in the Discovery Board now focused on issues that
span all composites as opposed to strategy and execution within each composite. HD Kallner, in addition to his primary role
as the Chief Executive Officer of Discovery Bank Limited, will resume his role as Chief Executive Officer of the Discovery business
composite in South Africa, with effect from 1 March 2023.
 L Chiume has been appointed as an independent non-executive director with effect from 18 September 2023. She is a member
of the Discovery Limited Audit Committee and the Group and South African Risk and Compliance Committees. She will bring a
wealth of financial services and investment experience.
 KC Ramon has been appointed as an independent non-executive director with effect from 18 September 2023. She is a
member of the Discovery Limited Audit Committee and the Social and Ethics Committee. She brings diverse leadership and
board experience in multiple sectors.
Changes in company secretary of Discovery Limited from 1 July 2022 to the date of this announcement are as follows:
 NN Mbongo resigned as the Group Company Secretary with effect from 31 March 2023 to pursue another opportunity outside the
Discovery Group.
 A Ceba was appointed as Group Company Secretary of Discovery with effect from 1 September 2023. In the interim, Ayanda
Manqele, the current Deputy Company Secretary, was appointed Acting Group Company Secretary, with effect from 31 May
2023 until 31 August 2023.
B.11. Dividend declaration in respect of the year ended 30 June 2023
B Preference share cash dividend declaration
On Tuesday, 5 September 2023, the directors declared a final gross cash dividend of 548.49315 cents (438.79452 cents net of
dividend withholding tax) per B preference share for the period 1 January 2023 to 30 June 2023, payable from the income reserves
of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 19 September 2023
Shares commence trading “ex” dividend 	Wednesday, 20 September 2023
Record date 	Friday, 22 September 2023
Payment date 	Tuesday, 26 September 2023
B preference share certificates may not be dematerialised or rematerialised between Wednesday 20 September 2023 and Friday 22
September 2023, both days inclusive.
Ordinary share cash dividend declaration
The Board of Directors declared a final gross cash dividend of 110 cents (88 cents net of dividend withholding tax) per ordinary
share, out of the income reserves of Discovery Limited. A dividend withholding tax of 20% will be applicable to all shareholders who
are not exempt.
The number of ordinary shares in issue at the date of declaration is 673 146 417.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 10 October 2023
Shares commence trading “ex” dividend 	Wednesday, 11 October 2023
Record date 	Friday, 13 October 2023
Payment date 	Monday, 16 October 2023
Share certificates may not be dematerialised or rematerialised between Wednesday, 11 October 2023 and Friday 13 October 2023,
both days inclusive.
Disclosure continued
for the year ended 30 June 2023

-- 32 of 50 --

35
C. 	ACCOUNTING POLICIES
C.1. 	New accounting standards effective
IFRS 9 financial instruments: general hedge accounting adopted effective 1 July 2022
The Group has elected to adopt and transition to IFRS 9 general hedge accounting prospectively from 1 July 2022. The revised
general hedge accounting requirements are better aligned with the entity’s risk management activities. The Group currently applies
hedge accounting to certain cash flow hedges of interest rate risk related to borrowings. The total hedge reserve remains unchanged
on transition. As at 1 July 2022, the risk management strategy and the hedge documentation for all micro hedges has been updated
to comply with the requirements of IFRS 9 general hedge accounting. The impact on the Group financial results, disclosures or
comparative information as a result of these amendments is immaterial.
C.2. 	New accounting standards not yet effective
IFRS 17 Insurance Contracts
The effective date of IFRS 17 Insurance Contracts is for reporting periods beginning on or after 1 January 2023, with comparative
restatement of the preceding year. IFRS 17 is therefore mandatory for the Discovery Group, effective from 1 July 2023, with
comparative restatement of the financial year ended 30 June 2023, including a restatement of the opening Statement of financial
position as at 1 July 2022.
IFRS 17 is a new accounting standard for insurance contracts that provides guidelines on recognising, measuring, presenting, and
disclosing insurance contracts. It was introduced by the International Accounting Standards Board (IASB) in May 2017. IFRS 17
replaces the previous standard, IFRS 4 Insurance Contracts, issued in 2005 as an interim standard with limited prescribed changes
to pre-existing insurance accounting practices applied by insurers.
IFRS 17 represents a positive step towards enhancing transparency, comparability, and understanding of how insurers earn profits
from insurance contracts, namely insurance service result and financial results. Consistent with the core objectives of IFRS 17,
Discovery has taken the opportunity to align its financial reporting approach and processes across its various jurisdictions where
insurance activities are undertaken.
The framework established by IFRS 17 outlines the specific requirements that companies must adhere to when reporting information
related to both the insurance contracts they issue and the reinsurance contracts they hold. One of the noteworthy distinctions
introduced by IFRS 17 pertains to the level of granularity at which insurance contracts are recognised and measured. Discovery is well-
prepared to embrace this enhanced granularity, as it aligns with the Group’s actuarial approach.
IFRS 17 is not limited to insurance companies but also those companies that issue any contract that results in transfer of significant
insurance risk. For Discovery, the contracts within the scope of IFRS 17 are almost entirely aligned with those recognised in IFRS 4.
Whilst the underlying contractual terms and economic risks and rewards of each insurance contract remain unaltered, IFRS 17
impacts the accounting treatment of insurance contracts and most notably the timing of recognition of insurance related profits and
losses for accounting purposes. Importantly, it also separates the insurance related profit or losses between those arising from
insurance service results and those arising from financial results.
IFRS 17 does not result in a change in the underlying business value of contracts, including:
 No direct change to cash flows or underlying risk and reward of contracts. Future tax cash flow impacts are expected to be
immaterial.
 Immaterial impact on regulatory or economic solvency, capital position and capital management.
 The ability to pay dividends unaffected as cash flows and solvency remain unchanged.
 Immaterial impact on Embedded Value.
Transition to IFRS 17 and estimated impact
Upon first-time adoption, IFRS 17 requires the standard to be applied fully retrospectively as if the standard always applied unless
impracticable. If impracticable to do so, the entity can elect to either apply a modified retrospective approach or use the fair value
approach.
As noted, Discovery is in a position to apply a fully retrospective restatement from inception for all material groups of insurance
contracts. Discovery did not measure any of its portfolios using the fair value approach.
The fully retrospective approach requires that Discovery identify, recognise, and measure groups of insurance contracts as if IFRS
17 had always applied. While this approach brought about significant complexity to the transition project, it has provided Discovery
with valuable historical insights as to how results will be impacted by model and assumption changes, changes in the discount rates
and extraordinary stress events such as the financial crisis of 2008/09 and the COVID-19 pandemic.

-- 33 of 50 --

36	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
C. 	ACCOUNTING POLICIES continued
C.2. 	New accounting standards not yet effective continued
Transition to IFRS 17 and estimated impact continued
Based on the work completed, the restatement is much more pronounced for the long-term insurance business of Discovery Life in
SA and VitalityLife in the UK. In contrast, the impact of the retrospective restatement is limited for the short-term businesses except
for VitalityHealth where the impact is more significant due to the change in treatment of insurance acquisition costs.
Discovery has assessed the estimated impact that the initial application of IFRS 17 will have on its financial statements. The changes
resulting from the transition to IFRS 17 can be summarised as follows:
 Those changes that result in differences to the IFRS 17 margins relative to the IFRS 4 margins. These changes result in concomitant
temporary changes in equity. For example, to the extent that changes resulted in the strengthening of contractual service margins
that will release to profit in future periods, such changes are mirrored by a reduction in shareholders’ equity upon transition.
 Other changes, such as remeasurement basis of the expected future cash flows or recognised assets and liabilities from short-
term insurance, e.g., deferred acquisition costs. These remeasurements would result in a change in equity on transition without
a visible offset of insurance margins but similarly will indirectly result in higher or lower net profits in future periods (for a
reduction or increase in equity respectively).
In the case of Discovery, increases in insurance margins, most notably Contractual Service Margin (CSM), have a far more
material impact. Such resulting increases of additional IFRS 17 margins on transition will be available as future profit. The main
cause for this significant increase in CSM margins is that Discovery has a more recent and rapidly growing history compared to very
long-standing insurers. As Discovery businesses mature, there is a point of convergence where the annual profit recognition under
IFRS 4 and IFRS 17 inevitably cross over.
The most significant changes that result in an increase in IFRS 17 margins relative to margins under IFRS 4, can be summarised as follows:
 The measurement under IFRS 17 includes only those cash inflows and outflows relating directly to the fulfilment of the group
of insurance contracts, termed directly attributable expenses. In addition to claims and benefits, these may include certain
directly attributable overhead expenses. However, non-directly attributable expenses such as general marketing and sponsorships,
allocated group executive and group function costs and research and development activities of new products, are not included
in the initial recognition value of the contract. Under IFRS 17, these non-directly attributable expenses are immediately
expensed and are therefore not considered when determining the Expected Fulfilment Cash Flows (EFCF) of the insurance
contracts being measured. The immediate expensing of such non-directly attributable expenses increases the available margin
on the portfolio compared to the IFRS 4 treatment where such expenses were brought into account when determining the
available margins. It should be noted that such expenses are brought into consideration when determining the pricing of
products and these increased IFRS 17 margins are therefore similarly available for recognition as profits in future or to absorb
adverse changes.
 Contracts are measured at a more granular level where portfolios are established and as a minimum with annual business
cohorts of no more than twelve months apart. Each of these cohorts is further categorised into separate groups based on
expected profitability being profitable, profitable at risk, and onerous groups. Losses are immediately expensed when they arise
on onerous contracts, effectively eliminating any cross-subsidisation or set-off applied within a portfolio. This immediate write-
off of shortfalls on contracts, effectively increases the available margin on the remainder of the portfolio, which will be
recognised to profit in future.
 Other items, including, amongst others, the different treatment of certain basis changes and variances through the margin, the
different rates at which interest is accreted on the margins, and small differences in the run-off of the margins over time, are
less material in the case of Discovery.
 Unlike IFRS 4, IFRS 17 separately recognises the finance related consequences of insurance contracts from the underlying
insurance activities. Finance income and expense related to insurance contracts (IFIE) and the changes in the measurement of
finance related items are recognised as IFIE either immediately in profit or loss or disaggregated and allocated using a
systematic allocation to profit or loss with variances being recognised through OCI.
 As will be noted below, Discovery has elected to apply the OCI option to certain long-term insurance contracts. The exclusion
of certain elements of IFIE from the profit or loss is largely aligned to the existing treatment where Discovery excludes the
impact of economic assumptions, net of associated derivatives, from its normalised profit and normalised headline earnings.
The use of OCI removes the need for this normalisation after adoption of IFRS 17.
Other changes, resulting in a change in equity on transition without a visible offset of insurance margins:
 The remeasurement of best estimates of the future fulfilment cash flows and measurement and accounting treatment of
insurance acquisition cash flows, i.e., deferred acquisition costs, on the short-term business lines and
 Associated deferred tax and future tax impacts of the changes noted above.
Disclosure continued
for the year ended 30 June 2023

-- 34 of 50 --

37
C. 	ACCOUNTING POLICIES continued
C.2. 	New accounting standards not yet effective continued
Transition to IFRS 17 and estimated impact continued
IFRS 17 acknowledges that different companies may manage their insurance contracts differently. As a result, IFRS 17 is principle-
based and permits several accounting policy elections. The following is a summary of these accounting elections and specific
elections made by Discovery:
Election 	Options 	Discovery elections
Transition approach 	Three transition approaches
 IFRS 17 requires full retrospective unless
impracticable.
 If full retrospective is impracticable, then
accounting election of modified
retrospective, or
 fair value approach.
 Given the availability of reliable and accurate
data and actuarial models, Discovery is
required to apply IFRS 17 fully retrospective
to all material groups of insurance contracts.
 For the remainder of portfolios, when
full retrospective was impracticable, then
modified retrospective was applied. Discovery
has not applied the fair value approach to
any groups of insurance contracts.
Changes in time value
of money (Insurance
finance income and
expense (IFIE)
presentation)
Two alternatives:
 Present all IFIE and IFIE changes in profit
or loss.
 Include IFIE in profit or loss using
systematic allocation. Remainder
recognised in OCI.
 The use of the OCI removes the volatility
from changes in IFIE (previously economic
assumptions) in the measurement of the
insurance contract. The amount recognised
in OCI is then reclassified to profit or loss
using a systematic allocation.
 Discovery has elected OCI on its long-term
life-insurance business lines in Discovery
Individual Life and VitalityLife. For the
remainder of business lines, the change in
measurement of the insurance contracts is
offset by a change in the measurement of
the assets backing those insurance contracts.
Risk adjustment 	 No prescriptive approach is provided
under IFRS 17.
 Discovery uses the confidence level
approach.
 For its long-term businesses and group life
insurance, Discovery sets the confidence
level at 90%.
 For its short-term businesses, Discovery sets
the confidence level at 75%.
Acquisition cost (for
portfolios at Premium
Allocation Approach
(PAA))
Two alternatives:
 The default under IFRS 17 for contracts
with PAA is to defer the insurance
acquisition cash flows and allocate the
expense to initial and renewal periods,
i.e., Defer acquisition costs and amortise.
 Entity can elect to immediately expense
insurance acquisition cash flows.
 VitalityHealth applies the default
requirement of IFRS 17. This treatment
results in a largely similar treatment to the
FinRe arrangements VitalityHealth held
under IFRS 4.
 For other insurance portfolios measured
using the PAA, Discovery has elected to
immediately expense in profit or loss the
insurance acquisition cash flows as these
are not significant.
Reflect time value of
money (i.e., discount)
in measuring coverage
units
Two alternatives:
 Reflect time value of money in measuring
coverage units.
 Don’t reflect time value of money in
measuring coverage units.
 Discovery elected to reflect time value
of money in the measurement of coverage
units. The discounting of coverage units
provides the most reasonable emergence
of profit, considering the projected level
of future margins on retained business
for Discovery.

-- 35 of 50 --

38	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
C. 	ACCOUNTING POLICIES continued
C.2. 	New accounting standards not yet effective continued
Estimated transitional impact
Based on the restatement work undertaken to date, the transition change is primarily a result of the increased IFRS 17 margins, as
represented by the CSM plus the risk adjustment. This adjustment, available for future profit release, falls within the range of R14.5
billion to R15.5 billion pre-tax. Other factors contributing to the change in equity include alterations in the methodology used to
determine fulfilment cash flows, difference in short-term business lines such as risk adjustment for non-financial risks, and the tax
effects of changes in the measurement of insurance contracts.
The concomitant net impact of transition adjustment (after tax) to the balance of the Group’s shareholders’ equity is estimated to
be as follows:
R million
Group total equity 30 June 2022
Audited and previously reported 	53 555
IFRS 17 adjustment, net of tax
Mainly resulting from the increases in the CSM and available for release to profit in future.
Accumulated IFIE recognised in OCI is less than 10% of total impact of shareholders equity 	(12 000 – 13 000)
Group total equity 1 July 2022
Restated 	41 555 – 40 555
As mentioned above, the impact of the above reduction in equity is effectively offset by a significant increase in insurance margins,
most notably CSM, that is available for release to profit in future years or to absorb any adverse changes.
On this basis, the total value created through the insurance activities of the Group remains largely unchanged, however, the timing
of recognition of insurance related profits has been deferred. The strengthened IFRS 17 margins result in higher future release of
profits and in less volatility due to its ability to absorb negative variances, while the election of OCI results in less volatility as a result
of its ability to manage variances in financial risks.
The material recognition, measurement and presentation policies of insurance contracts under IFRS 17 are set out in the Annual
financial statements for the year ended 30 June 2023, Annexure B – note 30 IFRS 17 Insurance Contracts.
C.3. 	Normalised headline earnings
Discovery assesses its performance using Normalised headline earnings, an alternative non-IFRS profit measure, alongside its IFRS
profit measures. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative
performance measure to enhance the comparability and understanding of the financial performance of the Group.
Non-IFRS measures are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures
and disclosures provided by other entities.
Discovery calculates headline earnings in accordance with the latest SAICA Circular ’Headline Earnings’. NHEPS is calculated by
starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal
operations as follows:
 Once-off transactions, for example restructuring costs, transaction costs related to interest rate derivatives and initial deferred
tax assets raised on previously unrecognised assessed losses.
 Unusual items – Discovery considers items to be unusual when they have limited predictive value or it is reasonable that items
of a similar nature would not necessarily arise for several future annual reporting periods. These adjustments include those
gains or losses impacting profit or loss associated with changes in economic assumptions used by long-term insurers in the
Group to the extent those are recognised in profit or loss, net of any gains or losses on derivatives to offset such changes in
economic assumptions; or
 Income or expenses not considered to be part of Discovery’s normal operations, for example amortisation of intangibles from
business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges.
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the
policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency.
Disclosure continued
for the year ended 30 June 2023

-- 36 of 50 --

39
C. 	ACCOUNTING POLICIES continued
C.4. 	Basis of preparation
Statement of compliance
Discovery Limited is a company incorporated in South Africa.
The summary consolidated financial statements for the year ended 30 June 2023 consolidate the results of Discovery and its
subsidiaries (together the Group) and equity account the Group’s interest in associates and joint ventures.
The annual results comprise the condensed consolidated statement of financial position at 30 June 2023, condensed consolidated
income statement, condensed consolidated statement of other comprehensive income, condensed consolidated statement of changes
in equity and condensed consolidated statement of cash flows for the year ended 30 June 2023 and selected explanatory notes.
The summary consolidated financial results are prepared in accordance with the JSE Limited Listings and Debt Listings Requirements,
IFRS Accounting Standards, including IAS 34 Interim Financial Reporting, the SAICA Financial Reporting Guides as issued by the
Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council as well as
the requirements of the South African Companies Act 71 of 2008. The accounting policies adopted are consistent with the
accounting policies applied in the prior annual financial statements, except as noted in C.1. New accounting standards effective.
Amendments to standards effective from 1 July 2022 do not have a material effect on the Group’s annual results. These annual results
do not include all the notes typically included in the annual financial statements and should therefore be read in conjunction with the
Group audited consolidated annual financial statements for the year ended 30 June 2023.
Audit
The summary consolidated financial statements are extracted from audited information but are not audited. The consolidated annual
financial statements for the year ended 30 June 2023 have been audited by the Group’s independent auditors PricewaterhouseCoopers
Inc. and KPMG Inc., who expressed an unmodified opinion thereon. The audited annual financial statements and the auditor’s report
thereon are available for inspection on the Company’s website. The directors of Discovery take full responsibility for the preparation
of this report and that the financial information has been correctly extracted from the underlying annual financial statements.

-- 37 of 50 --

40	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Embedded value statement
for the year ended 30 June 2023
The embedded value of the Discovery Group consists of the following components:
 the adjusted net worth attributed to the business at the valuation date;
 plus: the present value of expected future shareholder cash flows from the in-force covered business;
 less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax
shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose
distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new
business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and
cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business
includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery
Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health Insurance, Discovery
Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business.
In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference
shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
From June 2022, the VitalityLife embedded value has been adjusted to allow for the agreement with the Prudential Assurance Company (“PAC”)
in May 2022 to defer the transfer of the VitalityLife business on the PAC licence to the Vitality Life Limited licence (“the Part VII transfer”).
The 30 June 2023 embedded value results and disclosures were subjected to an external review.
TABLE 1: GROUP EMBEDDED VALUE
R million
Group
2023
Group
2022
%
change
Shareholders’ funds 	63 974 	53 555 	19
Adjustment to shareholders’ funds from published basis1 	(45 688) 	(39 764) 	15
Adjusted net worth2 	18 286 	13 791 	33
Value of in-force covered business before cost of required capital 	83 906 	76 077 	10
Cost of required capital 	(4 016) 	(3 610) 	11
Discovery Group embedded value 	98 176 	86 258 	14
Number of shares (millions) 	658.4 	657.0
Embedded value per share 	R149.11 	R131.29 	14
Diluted number of shares (millions) 	672.5 	668.3
Diluted embedded value per share3 	R145.99 	R129.07 	13
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the
closing exchange rate of R23.99/GBP (June 2022: R20.00/GBP).
R million
Group
2023
Group
2022
Life net assets under insurance contracts 	(25 491) 	(24 793)
Vitality Life Limited net assets under insurance contracts 	(12 051) 	(8 608)
VitalityHealth financial reinsurance asset 	(4 465) 	(3 021)
VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) 	(536) 	(450)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(13) 	(11)
Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture 	(2 969) 	(2 475)
Intangible assets (net of deferred tax) in covered businesses 	(893) 	(864)
Net preference share capital 	(779) 	(779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting 	1 333 	1 170
Equity settled share based payment mark-to-market adjustment 	176 	67
(45 688) 	(39 764)
The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market
value of the equity settled share based payments.

-- 38 of 50 --

41
2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded
value:
R million
Group
2023
Group
2022
Shareholders’ funds 	63 974 	53 555
Adjustment to shareholders’ funds 	(45 688) 	(39 764)
Adjusted net worth 	18 286 	13 791
Excess of available capital over adjusted net worth 	40 336 	35 342
Available capital 	58 622 	49 133
Required capital 	41 987 	38 658
Excess available capital 	16 635 	10 475
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This includes:
– The net preference share capital of R779 million which is included as available capital.
– The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth.
– The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
Group
2023
Group
2022
Health and Vitality 	1 108 	1 000
Life and Invest 	26 011 	25 403
VitalityHealth 	4 238 	3 164
VitalityLife 	10 630 	9 091
Total required capital 	41 987 	38 658
– For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
– For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
– For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement.
– For the VitalityLife business on the PAC licence, the required capital was set equal to 1.5 times the UK Solvency I long-term insurance capital requirement
as per the agreement with PAC following the long-term delay of the Part VII transfer. For the business sold on the Vitality Life Limited licence, the required
capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement. Note that for the prior period ended 30 June 2022, the total
required capital for VitalityLife was incorrectly reported as R9 751 million resulting in a total required capital of R39 318 million and total excess
available capital of R9 815 million. This misstatement has been corrected above, and did not affect the embedded value as at 30 June 2022.
3 The diluted embedded value per share adjusts for treasury shares held in the Discovery Group BEE Share Trust and as part of the Discovery Group’s
Long-term Incentive Plan where the impact is dilutive.
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
Value before cost of
required capital
Cost of required
capital
Value after cost of
required capital
at 30 June 2023
Health and Vitality 	25 985 	(512) 	25 473
Life and Invest1 	33 301 	(1 665) 	31 636
VitalityHealth2 	12 797 	(698) 	12 099
VitalityLife2 	11 823 	(1 141) 	10 682
Total 	83 906 	(4 016) 	79 890
at 30 June 2022
Health and Vitality 	24 528 	(479) 	24 049
Life and Invest1 	32 073 	(1 509) 	30 564
VitalityHealth2 	10 658 	(583) 	10 075
VitalityLife2 	8 818 	(1 039) 	7 779
Total 	76 077 	(3 610) 	72 467
1 Included in the Life and Invest value of in-force covered business is R2 005 million (June 2022: R1 734 million) in respect of investment management services
provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R23.99/GBP (June 2022: R20.00/GBP).

-- 39 of 50 --

42	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Embedded value statement continued
for the year ended 30 June 2023
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
R million
Group
2023
Group
2022
Embedded value at end of period 	98 176 	86 258
Less: embedded value at beginning of period 	(86 258) 	(74 645)
Increase in embedded value 	11 918 	11 613
Net change in capital1 	– 	(10)
Dividends paid 	69 	56
Transfer to hedging reserve 	(76) 	(309)
Employee share option schemes 	(553) 	(326)
Increase in treasury shares 	– 	–
Acquisition of subsidiaries with non-controlling interest 	(6) 	–
Embedded value earnings 	11 352 	11 024
Annualised return on opening embedded value 	13.2% 	14.8%
1 The net change in capital reflects share issues (net of costs and proceeds) and an increase (decrease) in treasury shares in the period.
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
Group 2023 	Group 2022
R million
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Embedded
value
Embedded
value
Total profit from new business (at point of sale) 	(5 213) 	(302) 	6 955 	1 440 	2 061
Profit from existing business
– 	Expected return 	7 196 	(33) 	1 426 	8 589 	6 799
– 	Change in methodology and assumptions1 	1 989 	172 	(7 015) 	(4 854) 	867
– 	Experience variances 	716 	68 	2 420 	3 204 	3 124
Impairment, amortisation and fair value adjustment2 	(67) 	– 	– 	(67) 	(52)
Increase in goodwill and intangibles 	(263) 	– 	– 	(263) 	(418)
Other initiatives 3 	– 	– 	24 	24 	(836)
Non-recurring expenses 	(193) 	– 	– 	(193) 	(130)
Acquisition costs4 	(50) 	– 	2 	(48) 	(41)
Finance costs 	(2 848) 	– 	– 	(2 848) 	(2 318)
Foreign exchange rate movements 5 	1 365 	(312) 	4 017 	5 070 	1 171
Other 6 	89 	1 	– 	90 	(16)
Return on shareholders’ funds7 	1 208 	– 	– 	1 208 	813
Embedded value earnings 	3 929 	(406) 	7 829 	11 352 	11 024
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the
operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded
value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure
in Discovery Group Europe Limited.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health Insurance) and costs of start-up
businesses (including Discovery Bank, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which relate to
non-covered business are also included in this item.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been
written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value
of new business and therefore the costs are not deducted from the value of new business.
5 This item includes foreign exchange gains/(losses) emerging through the income statement, in addition to translation impacts on the cost of required capital
and value of in-force.
6 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth.
7 The return on shareholders’ funds is shown net of tax and management charges.

-- 40 of 50 --

43
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Renewal expenses 	67 	– 	32 	2 	(93) 	– 	(16) 	– 	(8)
Lapses and surrenders 1,2 	(4) 	(78) 	1 	189 	– 	372 	(161) 	218 	537
Mortality and morbidity 	– 	– 	130 	(79) 	(93) 	– 	34 	– 	(8)
Policy alterations2 	– 	(5) 	(521) 	163 	– 	– 	30 	(54) 	(387)
Backdated cancellations 	– 	– 	– 	– 	– 	– 	– 	– 	–
Premium and fee income 3 	150 	– 	14 	232 	218 	– 	7 	61 	682
Inflation-linked indexation2,4 	– 	– 	4 	242 	– 	– 	(107) 	606 	745
Economic 5 	– 	– 	260 	284 	64 	– 	(2) 	– 	606
Commission 	– 	– 	– 	– 	(36) 	– 	– 	– 	(36)
Tax 6 	110 	– 	305 	(307) 	(33) 	– 	46 	– 	121
Reinsurance 	– 	– 	– 	– 	84 	– 	(106) 	46 	24
Maintain modelling term7 	– 	335 	– 	137 	– 	117 	– 	– 	589
Vitality benefits 	(32) 	– 	– 	– 	– 	– 	(5) 	– 	(37)
Other 8 	161 	(1) 	(58) 	35 	19 	– 	247 	(27) 	376
Total 	452 	251 	167 	898 	130 	489 	(33) 	850 	3 204
1 For Health and Vitality, the lapse and surrender experience was driven by the termination of an in-house scheme for the period under review – excluding this
impact would have resulted in a positive experience variance for the business. For VitalityHealth, the experience reflects improved retention rates from strong
performance across all channels coupled with a continued focus on renewal pricing strategies. Better than expected lapse experience has been observed for
the other covered businesses.
2 For Life and Invest, the policy alterations experience relates mainly to acquisition costs on positive servicing, but should be considered in the context
of the overall positive lapse and surrender and economic experience variances given its correlation to current economic conditions and the high
inflationary environment.
3 Other than higher than expected premium and fee income, this experience variance item includes the impact of positive integration experience for Individual
Life, and an increased demand for private medical insurance in the United Kingdom improving premium retention for VitalityHealth.
4 This experience variance relates to premium and benefit increases for inflation-linked policies, net of increase holidays. During the period the actual inflation
was higher than expected for those policies passing through an anniversary increase in-period. In previous embedded value statements, this experience
variance was included under economic experience. Due to the significance of these experience variances in the current period as a result of the high
inflationary environment, this amount has been shown separately.
5 For Life and Invest, the experience includes higher than expected growth in asset values in the Invest business.
6 The tax variance arises due to the timing difference between the expected tax payments and actual payments.
7 For Health and Vitality, Life and Invest and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises because
the total term of the in-force covered business is effectively increased by twelve months.
8 The key Other experience relates to cash flow timing variances in Life and Invest, profits and losses from companies within the Health, VitalityHealth and
VitalityLife segments which are not part of covered business, including the net impact of the VitalityLife swaption program, excluding gains or losses from
the hedge which are included in the economic assumption changes item.

-- 41 of 50 --

44	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Embedded value statement continued
for the year ended 30 June 2023
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Modelling changes 1 	41 	– 	(121) 	202 	– 	– 	48 	(190) 	(20)
Expenses 2 	– 	(495) 	5 	(133) 	– 	– 	– 	– 	(623)
Lapses3 	– 	– 	(170) 	(1 115) 	– 	– 	– 	– 	(1 285)
Mortality and morbidity 4 	– 	– 	– 	– 	– 	– 	81 	(219) 	(138)
Benefit changes 	– 	(18) 	– 	– 	– 	– 	– 	– 	(18)
Vitality 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 	– 	– 	– 	– 	– 	– 	– 	(13) 	(13)
Economic assumptions 5 	– 	(1 318) 	23 	(2 126) 	– 	(1 072) 	106 	(293) 	(4 680)
Premium and fee income6 	– 	1 084 	108 	454 	– 	– 	– 	– 	1 646
Reinsurance and financing 7 	– 	– 	1 867 	(1 735) 	– 	63 	– 	– 	195
Other 	– 	– 	1 	81 	– 	– 	– 	– 	82
Total 	41 	(747) 	1 713 	(4 372) 	– 	(1 009) 	235 	(715) 	(4 854)
1 For Health and Vitality and Life and Invest, the item reflects refinements to the data and models. For VitalityLife, the item reflects modelling improvements
related to commission and reinsurance.
2 For Health and Vitality and Life and Invest, the expense assumption update reflects an alignment to the expense budget for the next financial year.
3 For Life and Invest, the long-term decrement basis was reviewed and updated in line with lower exit rates observed on certain Invest product lines, and a
short-term allowance for elevated expected lapse and policy alterations experience on the Life business.
4 For VitalityLife, the mortality basis, with respect to future mortality improvements, and the serious illness cover basis was reviewed. The existing shared value
model was reviewed and replaced with a new model to more appropriately capture the impact that shared value has on the business’ underlying
demographic basis.
5 For Health and Vitality and Life and Invest, the economic assumptions were updated in line with observed market nominal and real yield risk-free curves at
30 June 2023. For VitalityLife, the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest rates,
offset by the net change in the interest rate hedge. For VitalityHealth, the impact of updating the assumptions relative to the Solvency II yield curves results
in a reduction to the annuity factor.
6 For Health and Vitality, the premium and fee income item relates to an update of the administration fee income escalations for certain plans recently
renewed. For Life and Invest, Invest fee structures were reviewed in response to updated persistency expectations.
7 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected cash flows
arising from part of the negative reserves are monetised to match other positive policy liabilities.

-- 42 of 50 --

45
TABLE 7: EMBEDDED VALUE OF NEW BUSINESS
R million
Group
2023
Group
2022
%
Change
Health and Vitality
Present value of future profits from new business (at point of sale) 	954 	958
Cost of required capital 	(39) 	(30)
Present value of future profits from new business (at point of sale) after cost
of required capital 	915 	928 	(1)
New business annualised premium income1 	4 959 	4 185 	18
Life and Invest
Present value of future profits from new business (at point of sale)2 	516 	795
Cost of required capital 	(87) 	(90)
Present value of future profits from new business (at point of sale) after cost of
required capital 	429 	705 	(39)
New business annualised premium income3 	2 965 	2 995 	(1)
Annualised profit margin4 	1.8% 	3.0%
Annualised profit margin excluding Invest business 	2.5% 	5.3%
VitalityHealth 5
Present value of future profits from new business (at point of sale) 	269 	398
Cost of required capital 	(87) 	(81)
Present value of future profits from new business (at point of sale) after cost of
required capital 	182 	317 	(43)
New business annualised premium income6 	2 001 	1 648 	21
Annualised profit margin4 	1.4% 	2.6%
VitalityLife 7
Present value of future profits from new business (at point of sale) 	3 	219
Cost of required capital 	(89) 	(108)
Present value of future profits from new business (at point of sale) after cost of
required capital 	(86) 	111 	(177)
New business annualised premium income 	1 124 	882 	27
Annualised profit margin4 	(1.0%) 	1.4%
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown
above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums
in respect of new business written during the period but only activated after 30 June 2023.
The total Health and Vitality new business annualised premium income written over the period was R9 051 million (June 2022: R7 548 million).
2 Included in the Life and Invest embedded value of new business is R21 million (June 2022: R54 million) in respect of investment management services
provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been
recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium
is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded
after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the
reporting period, including policies whose first premium is due after the valuation date.
The new business annualised premium income of R2 965 million (June 2022: R2 995 million) (single premium APE: R1 430 million (June 2022:
R1 421 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business
annualised premium income written over the period, including automatic premium increases of R2 208 million (June 2022: R1 801 million) and servicing
increases of R716 million (June 2022: R668 million), was R5 889 million (June 2022: R5 464 million) (single premium APE: R1 499 million (June 2022:
R1 492 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans are shown in Table 5 as
experience variances and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date
multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for
the Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised
premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month,
as well as premiums in respect of new business written during the period but only activated after 30 June 2023.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date.

-- 43 of 50 --

46	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Embedded value statement continued
for the year ended 30 June 2023
Basis of preparation
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
Group
2023
Group
2022
Beta coefficient 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5
Risk discount rate (%)
– 	Health and Vitality1 	15.125 	14.375
– 	Life and Invest1 	15.875 	14.875
– 	VitalityHealth 	7.000 	5.016
– 	VitalityLife 	7.042 	4.997
Rand/GBP exchange rate
Closing 	23.99 	20.00
Average 	21.43 	20.25
Margin over Expense inflation to derive Medical inflation (%)
South Africa 	3.00 	3.00
Expense inflation (%)2
South Africa 	– 	Health and Vitality 	7.96 	7.85
– 	Life and Invest 	8.13 	7.74
United Kingdom 	3.75 	3.75
Pre-tax investment return (%)
South Africa 	– 	Cash1 	11.75 	10.75
– 	Life and Invest bonds3 	13.25 	12.25
– 	Health and Vitality bonds3 	12.50 	11.75
– 	Equity1 	16.75 	15.75
United Kingdom 	– 	VitalityHealth risk-free rate 	4.38 	2.39
– 	VitalityLife risk-free rate 	4.42 	2.37
– 	VitalityLife IFRS interest rate 	3.98 	2.92
– 	VitalityLife investment return 	4.31 	2.00
Long-term corporation tax rate (%)
South Africa 	27 	27
United Kingdom 	25 	25
VitalityHealth Assumptions
– 	Margin (net of tax and cost of capital) (%) 	12.05 	12.00
– 	Annuity Factor 	6.28 	7.00
Projection term
– 	Health and Vitality 	20 years 	20 years
– 	Discovery Life – VIF 	40 years 	40 years
– 	Group Life 	20 years 	20 years
– 	VitalityLife 	No cap 	No cap
– 	VitalityHealth4 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted
average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.

-- 44 of 50 --

47
The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach with
specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount
rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed
beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta
will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long time period suggest
the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic
performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may
want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery
Group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of
an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publicly available JSE risk-free
nominal yield curve.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the
net investment return assumption.
The risk-free rate assumption for VitalityHealth and VitalityLife was based on the single interest rate derived from the Prudential Regulatory
Authority yield curve. The inflation rate is consistent with the long-term market view of inflation.
From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the
Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse
rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The assumptions underlying the
Annuity Factor and Margin are set taking into account the current experience in the business at different durations.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible
assets. The Vitality Life Limited and the VitalityLife business on the PAC licence required capital amount is assumed to earn the investment
return assumption, which is set based on the return on a portfolio of government and corporate bonds assumed to back the required
capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow available after
having met both the required capital amount and an internally defined liquidity target capital requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into
account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.

-- 45 of 50 --

48	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023	 	49
Embedded value statement continued
for the year ended 30 June 2023
Sensitivity to the embedded value assumptions
The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the
historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors
may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the
embedded value and the embedded value of new business at 30 June 2023 to changes in the risk discount rate is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action
such as risk premium increases where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change	R million
Adjusted
net worth2
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	18 286 	25 985 	(512) 	33 301 	(1 665) 	12 797 	(698) 	11 823 	(1 141) 	98 176
Impact of:
Risk discount rate + 1% 	18 286 	24 563 	(551) 	30 350 	(1 759) 	12 160 	(664) 	11 106 	(1 002) 	92 489 	(6)
Risk discount rate – 1% 	18 286 	27 555 	(467) 	36 786 	(1 555) 	13 501 	(737) 	12 625 	(1 310) 	104 684 	7
Lapses – 10% 	18 054 	26 824 	(536) 	36 226 	(1 760) 	14 943 	(815) 	12 579 	(1 374) 	104 141 	6
Interest rates – 1% 1 	17 316 	25 887 	(494) 	33 841 	(1 636) 	13 501 	(737) 	11 987 	(1 454) 	98 211 	–
Equity and property market value – 10% 	18 247 	25 985 	(512) 	32 595 	(1 658) 	12 797 	(698) 	11 823 	(1 141) 	97 438 	(1)
Equity and property return + 1% 	18 286 	25 985 	(512) 	33 657 	(1 665) 	12 797 	(698) 	11 823 	(1 141) 	98 532 	–
Renewal expenses – 10% 	18 402 	28 602 	(473) 	33 978 	(1 636) 	13 925 	(698) 	12 077 	(1 126) 	103 051 	5
Mortality and morbidity – 5% 	18 560 	25 985 	(512) 	35 550 	(1 544) 	14 876 	(698) 	12 279 	(1 105) 	103 391 	5
Projection term + 1 year 	18 286 	26 295 	(517) 	33 391 	(1 667) 	12 889 	(703) 	11 823 	(1 141) 	98 656 	–
1 All economic assumptions were reduced by 1%.
2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: 	VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change	R million
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Base 	954 	(39) 	516 	(87) 	269 	(87) 	3 	(89) 	1 440
Impact of:
Risk discount rate + 1% 	875 	(43) 	341 	(92) 	170 	(82) 	(103) 	(75) 	991 	(31)
Risk discount rate – 1% 	1 040 	(36) 	718 	(81) 	379 	(93) 	122 	(107) 	1 942 	35
Lapses – 10% 	1 022 	(43) 	707 	(92) 	509 	(100) 	120 	(106) 	2 017 	40
Interest rates – 1%1 	960 	(38) 	508 	(85) 	379 	(93) 	90 	(123) 	1 598 	11
Equity and property return + 1% 	954 	(39) 	543 	(87) 	269 	(87) 	3 	(89) 	1 467 	2
Renewal expense – 10% 	1 094 	(37) 	567 	(85) 	399 	(87) 	41 	(85) 	1 807 	25
Mortality and morbidity – 5% 	954 	(39) 	609 	(80) 	508 	(87) 	39 	(82) 	1 822 	27
Projection term + 1 year 	970 	(40) 	521 	(87) 	284 	(87) 	3 	(89) 	1 475 	2
Acquisition costs – 10% 	985 	(39) 	686 	(87) 	317 	(87) 	172 	(89) 	1 858 	29
1 All economic assumptions were reduced by 1%.

-- 46 of 50 --

50	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Annexure A
This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative non-IFRS profit and income
measures. These measures enhance the comparability and understanding of the financial performance of the Group.
NEW BUSINESS ANNUALISED PREMIUM INCOME
for the year ended 30 June 2023
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of the
Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, Discovery Health
Medical Scheme’s (DHMS) new business is attributable to the medical scheme but is under the administration and marketing of Discovery
Health which earns a fee in respect of such services.
Core new business API increased by 6% for the year ended 30 June 2023 when compared to the same period in the prior year. Core new
business API, excluding products of VitalityInvest and PAHI reinsurance business in run down, increased by 12% for the year ended
30 June 2023 when compared to the corresponding prior period.
R million
Group
2023
Group
2022
%
Change
Discovery Health1 	8 678 	7 292 	19
Discovery Life 	2 838 	2 543 	12
Individual Life 	2 663 	2 362 	13
Group Life 	175 	181 	(3)
Discovery Invest 	3 050 	2 920 	4
Discovery Insure 	1 249 	1 246 	–
Discovery Vitality 	372 	256 	45
SA new initiatives2 	631 	839 	(25)
Total new business API from SA Composite 	16 818 	15 096 	11
Vitality Health 	2 064 	1 738 	19
Vitality Life 	1 721 	1 256 	37
Subtotal – continuing products 	3 785 	2 994 	26
VitalityInvest 	53 	737 	(93)
Total new business API from UK Composite 	3 838 	3 731 	3
Total new business API from VG Composite: Ping An Health Insurance (PAHI) 	2 369 	2 883 	(18)
PAHI own licence 	2 185 	2 214 	(1)
PAHI reinsurance business3 	184 	669 	(72)
Core new business API of Group (as previously disclosed) 	23 025 	21 710 	6
Core new business API of Group, excluding products in run down of VitalityInvest
and PAHI reinsurance business (restated) 	22 788 	20 304 	12
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and
offerings such as GAP cover and FlexiCare cover. The new business API for New Closed Schemes includes contracted new business API and business in the first
twelve months of on-boarding. Closed Schemes refer to those restricted to certain employers and industries.
2 Other group initiatives include the Umbrella Fund and Discovery Insure commercial.
3 PAHI’s reinsurance business is largely closed to new business following the restructured co-operation with Ping An Life
Calculation of New business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single
premium policies It also includes both automatic premium increases and servicing increases on existing long-term insurance policies. The
amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a result of:
 The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is included
from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above, new
business is included when the policy has been contractually committed.
 Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above but
excluded in the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business
disclosures between the embedded value and the table above.

-- 47 of 50 --

51
INCOME FROM NON-INSURANCE BUSINESS LINES
for the year ended 30 June 2023
(not included in new business API definition above)
R million
Group
2023
Group
2022 	Change %
Discovery Health – Income excluded from API measure 	1 201 	1 090 	10
Discovery Bank 	1 517 	951 	60
Discovery Bank – Net banking fee and commission income (NIR) 	943 	633 	49
Discovery Bank – Net bank interest and similar income (NII) 	574 	318 	81
Income Vitality Global1 	2 222 	1 398 	59
Vitality Network 	1 236 	1 031 	20
Vitality Health International (excluding PAHI) 	986 	367 	169
Total income from non-insurance business lines 	4 940 	3 439 	44
1 Vitality Global income includes gross recurring and lump sum revenues earned by Vitality Group and specifically excludes revenue related to cost recoveries
and rewards.

-- 48 of 50 --

52	DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2023
Transfer secretaries Computershare Investor Services (Pty) Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors Rand Merchant Bank (A division of FirstRand Bank Limited)
Secretary and registered office A Ceba, Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: 	DSY ISIN: ZAE000022331
JSE share code: 	DSBP ISIN: ZAE000158564
JSE company code: 	DSYI
1 Discovery Place, Sandton 2196 PO Box 786722, Sandton 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), HL Bosman1, L Chiume3, R Farber, WM Hlahla, HD Kallner*2,
FN Khanyile, NS Koopowitz*2, D Macready, Dr TV Maphai, T Mboweni, Dr A Ntsaluba*2, A Pollard*2, KC Ramon3, M Schreuder, B Swartzberg*,
B van Kralingen, DM Viljoen* (Group Chief Financial Officer), SV Zilwa.
* Executive.
1 Retired effective 1 December 2022.
2 Stepped down from the Board effective 1 March 2023 as part of changes in governance structures.
3 Appointed effective 18 September 2023.
Debt officer DM Viljoen
Annual financial results
– prepared by G Pieterse CA(SA), J Symons CA(SA)
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA
Administration

-- 49 of 50 --

Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Copyright 2021. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group.
Registration number: 1999/007789/06. Companies in the Group are licensed insurers and authorised financial services providers.

-- 50 of 50 --